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ABSTRACT 
 
Rationale: Targeted genetic engineering using programmable nucleases such as transcription activator–like 
effector nucleases (TALENs) is a valuable tool for precise, site-specific genetic modification in the human 
genome.  
 
Objective: The emergence of novel technologies such as human induced pluripotent stem cells (iPSCs) and 
nuclease-mediated genome editing represent a unique opportunity for studying cardiovascular diseases in 
vitro.  
 
Methods and Results: By incorporating extensive literature and database searches, we designed a collection 
of TALEN constructs to knockout (KO) eighty-eight human genes that are associated with 
cardiomyopathies and congenital heart diseases. The TALEN pairs were designed to induce double-strand 
DNA break near the starting codon of each gene that either disrupted the start codon or introduced a 
frameshift mutation in the early coding region, ensuring faithful gene KO. We observed that all the 
constructs were active and disrupted the target locus at high frequencies. To illustrate the general utility of 
the TALEN-mediated KO technique, six individual genes (TNNT2, LMNA/C, TBX5, MYH7, ANKRD1, and 
NKX2.5) were knocked out with high efficiency and specificity in human iPSCs. By selectively targeting a 
dilated cardiomyopathy (DCM)-causing mutation (TNNT2 p.R173W) in patient-specific iPSC-derived 
cardiac myocytes (iPSC-CMs), we demonstrated that the KO strategy ameliorates the DCM phenotype in 
vitro. In addition, we modeled the Holt-Oram syndrome (HOS) in iPSC-CMs in vitro and uncovered novel 
pathways regulated by TBX5 in human cardiac myocyte development.  
 
Conclusion: Collectively, our study illustrates the powerful combination of iPSCs and genome editing 
technology for understanding the biological function of genes and the pathological significance of genetic 
variants in human cardiovascular diseases. The methods, strategies, constructs and iPSC lines developed in 
this study provide a validated, readily available resource for cardiovascular research. 
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Genome editing, iPSCs, gene knockout, dilated cardiomyopathy, Holt-Oram syndrome, stem cell, cardiac, 
gene targeting, disease modeling. 
 
Nonstandard Abbreviations and Acronyms: 
 
cTAL  cardiomyopathy TALEN-based 
DSB  Double-strand break  
ECM  Extracellular matrix  
HOS  Holt-Oram syndrome  
iPSCs  induced pluripotent stem cells  
iPSC-CMs iPSC-derived cardiac myocytes  
NHEJ  non-homologous end joining  
SMRT  single-molecule real-time  
TALENs transcription activator–like effector nucleases  
TSS  transcription starting sites  
EADs  Early after depolarizations   

















Cardiovascular disease is a major cause of morbidity and mortality around the world. In recent 
years, exciting progress has been made in defining the etiology of congenital heart disease (CHD)1 and 
inherited cardiomyopathies,2 including hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy 
(DCM), left ventricular non-compaction (LVNC), and arrhythmogenic right ventricular 
cardiomyopathy/dysplasia (ARVC/D). Recent advances in genomics and molecular medicine have 
identified genetic mutations in plethora of genes that are implicated in the pathogenesis of inherited 
cardiomyopathies. Although the molecular analysis efforts have revealed important insights regarding the 
role of genetics in cardiomyopathies, the underlying molecular mechanisms remain poorly understood and 
the genotype-phenotype relationship from the ever-growing number of disease-associated gene mutations 
remains to be established.  
 
Recent advances in technologies for genome editing using site-specific nucleases,3 such as zinc 
finger nucleases (ZFNs), transcription activator–like effector nucleases (TALENs), and the clustered 
regularly interspaced short palindromic repeat/CRISPR-associated protein 9 (CRISPR/Cas9) system, offer 
a powerful tool for reverse genetics, genome engineering, and targeted transgene integration experiments 
to be performed in a precise and predictable manner. The use of engineered nucleases to make targeted, 
permanent changes to genes have revolutionized molecular genetics and present an alternative to the more 
established method of RNA interference (RNAi)-mediated knockdown using short hairpin RNA (shRNA) 
or short interfering RNA (siRNA). However, the RNAi-mediated post-transcriptional down-regulation of 
gene expression without changing the genetic code does not completely shut off the gene of interest.4 In 
most cases, functional RNA or protein remains and is translated albeit at lower levels. Thus, the gene 
function is reduced, but not eliminated. By contrast, genome editing changes the genetic code and typically 
causes a functional “knockout” (KO), or complete elimination of the gene function. The nucleases cut both 
DNA strands of the targeted locus generating a double-strand break (DSB) in the chromosome, which is 
then repaired by the non-homologous end joining (NHEJ) mechanism that re-ligates the two free 
chromosome ends. However, NHEJ is error-prone, often resulting in small insertions or deletions that can 
disrupt, or knockout, the gene of interest.  
 
Over the past decade, the advent of the human induced pluripotent stem cell (iPSC) technology, 
and the improvements in the differentiation method of iPSCs into specific cell types, such as cardiac 
myocytes (iPSC-CMs)5, endothelial cells (iPSC-ECs),6 and smooth muscle cells (iPSC-SMCs),7 provide an 
unprecedented opportunity for the generation of patient-specific in vitro models for disease modeling. 
Combining genome editing and iPSC technologies can successfully create human-based cell knockout 
models in vitro. Such models could improve our understanding of the underlying pathological mechanisms, 
and potentially lead to novel therapies.8 
 
In this study, we describe the design, construction, and validation of a cardiomyopathy TALEN-
based (cTAL) panel to knock out a comprehensive set of genes associated with cardiovascular diseases. We 
demonstrated the utility of this panel, and presented two case studies that provided novel insights into the 
pathogenesis of genetic cardiovascular disease. The readily available cTAL panel will allow researchers to 
fast-track projects by providing a validated panel of TALEN constructs for gene KO genome editing. This 

















TALEN genomic binding sites were designed using the TAL Effector Nucleotide Targeter 2.0,9 with the 
following constraints: (i) having a repeat array length of 15 repeat variable di-residue domains, and (ii) 
having a spacer length of 14–18 nucleotides. A preceding T base in position “0” anchored each binding site 
as has been shown to be optimal for naturally occurring TAL proteins.10,11 Each custom TALEN was 
generated from a library of 832 plasmids through a five-piece subcloning ligation: three sequence-specific 
tetramer-recognition pieces, one trimer-recognition piece, and an expression vector backbone (pTAL) as 
previously described.12 Briefly, the tetramer or trimer TAL repeats were digested out of library plasmids 
with the restriction enzyme BsmBI (NEB), gel purified, and subcloned into the pTAL vectors. The forward 
and reverse TALENs were subcloned into the pTAL_GFP and pTAL_RFP backbones, respectively. The 
sequences of all constructs used in this study are provided in the Supplemental Information. The TALEN 
plasmids will be available from Addgene. The cell lines are available upon request from the Stanford CVI 
iPSC Biobank (http://med.stanford.edu/scvibiobank.html). 
 
Culture and cardiac differentiation of iPSCs.  
The human iPSC lines (SCVI-15, SCVI-114, and SCVI-19) were obtained from the Stanford CVI iPSC 
Biobank. The iPSCs were maintained under feeder-free conditions in defined E8 media (Life Technologies) 
on tissue culture plates coated with hESC-qualified Matrigel (BD Biosciences) in 5% CO2/5% O2/90% N2 
environment at 37°C. Human iPSCs were differentiated toward cardiac myocytes using a small molecule 
mediated directed differentiation protocol.13 Briefly, cardiac differentiation was initiated by treatment with 
recombinant BMP4 and Activin A (Day 0-3), followed by treatment with 5 μM IWR-1 for 72 hr (day 4 to 
day 6).  
 
TALEN transfection.  
Human iPSCs were enzymatically dissociated with Accutase (Sigma) and plated on Matrigel coated dishes 
at 1:3 ratio in E8 supplemented with 10 um Y-27632 (Selleck Chemicals). 24 – 48 hr later, human iPSCs 
were dissociated with Accutase into single cells. ~2x106 cells were transfected with a pair of TALENs 
(1.0 μg of each TALEN) by nucleofection using the Amaxa 4D Nucleofector system (Lonza) with the P3 
Primary Cell Nucleofector Kit and program CM-150 per manufacturer’s instructions (Lonza). Following 
nucleofection, iPSCs were re-suspended in 1 ml pre-warmed E8 supplemented with 5 μM Thiazovivin and 
then plated in 6-well plates pre-coated with Matrigel and allowed to recover for 48 hr. 
 
SMRT sequencing.  
Genome-editing outcomes at the endogenous loci were quantified using single-molecule real-time (SMRT) 
DNA sequencing as previously described.14 Genomic DNA was extracted from TALEN-transfected iPSCs 
at 72 hr post-nucleofection without enrichment for transfected cells, and used as a template for PCR 
amplification using primer pairs designed to amplify a ~500 bp fragment surrounding the TALEN targeted 
loci. The PCR amplicons were purified using the nucleotide removal kit (Qiagen) and the sequencing 
libraries were constructed using the DNA Template Prep Kit 1.0 (Pacific Biosciences). SMRTbell libraries 
contained amplicons that were pooled together with different barcodes appended to allow multiplex 
analysis. Purified, closed circular SMRTbell libraries were annealed with a sequencing primer 
complementary to a portion of the single-stranded region of the hairpin. For all SMRTbell libraries, 
annealing was performed at a final template concentration between 30 and 60 nM, with a 20-fold molar 
excess of sequencing primer. All annealing reactions were carried out at 80°C for 2 min, with a slow cool 
to 25°C at a rate of 0.1°C/s. Annealed templates were stored at −20°C until polymerase binding. DNA 
polymerase enzymes were stably bound to the primed sites of the annealed SMRTbell templates using the 
DNA Polymerase Binding Kit 2.0 (Pacific Biosciences). SMRTbell templates (3 nM) were incubated with 
6 nM of polymerase in the presence of phospholinked nucleotides at 30°C for 2 hr. Following incubation, 
samples were stored at 4°C. Sequencing was performed within 72 hr of binding using a final concentration 
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of 0.3 nM. Each sample was sequenced using the DNA Sequencing Kit 2.0 (Pacific Biosciences). 
Sequencing data collection was performed on the PacBio RS (Pacific Biosciences) using C2/C2 chemistry 
and movies of 55 min in each case. The SMRT Sequencing Analysis pipeline was implemented in 
Strawberry Perl and utilizes the NCBI BLAST software as well as the mEmboss Needleman-Wunsch 
pairwise alignment algorithm. 
 
Isolation of targeted clonal cell populations.  
TALEN-transfected iPSCs were washed once with PBS and enzymatically dissociated with Accutase for 
3-5 min at 37°C followed by gently pipetting to ensure single cell suspension. The cells were washed once 
in PBS and re-suspended in E8 supplemented with Y-27632 (10 um). Double GFP+/RFP+ cells were then 
sorted by fluorescence activated cell sorter (FACSAria II; BD Biosciences), plated on 6-well plates at a 
clonal density of 1,000 cells/well and allowed to recover. After 7-10 days, putative single cell- derived 
clones were manually picked, expanded, and maintained in standard conditions.  
 
RNA-sequencing.  
Total RNA was isolated with the RNeasy Isolation kit with on-column DNase I treatment (Qiagen), and the 
quality of the RNA samples was assessed using the Agilent Bioanalyzer 2100 (Agilent). ERCC spike-in 
synthetic transcripts were added at manufacturer’s recommended amounts (Life Technologies) and 1 µg of 
each RNA was enriched for poly-A RNA using the Dynabeads® mRNA Direct Kit (Life Technologies) per 
manufacturer’s protocol. Whole transcriptome library preparation was performed using 5-10 ng of 
fragmented enriched poly-A RNA according to the manufacturer's protocol (Ion Total RNA-Seq Kit V2 
protocol; Life Technologies), followed by purification with AMPure beads (Beckman-Coulter Genomics). 
The quality and quantity of the libraries was assessed using the Agilent Bioanalyzer High Sensitivity Chip 
(Agilent). Each library concentration was adjusted to 100 pM and 70 ul were used for Ion Template 
preparation in the automated Ion Chef system and loaded on the Ion PI Chip Kit v2 (Life Technologies). 
Sequencing was performed in the Ion Proton sequencing platform using the Ion PI™ Sequencing 200 Kit 
v3 per manufacturer’s protocol (Life Technologies). Base calls were collected with Ion Torrent Suite 
software (Life Technologies). 
 
Allelic discrimination by digital PCR.  
Total RNA was extracted from iPSC-CMs at day 30 post-differentiation using RNeasy Mini Kit (Qiagen), 
and complementary DNA (cDNA) preparation was carried out using the iScript cDNA Synthesis Kit (Bio-
Rad Laboratories). The concentration of cDNA was reduced to about 0.2 ng/μl RNA equivalent and 1 ng 
(5 μl of 0.2 ng/μl) of RNA-equivalent cDNA was mixed with primers, probes and ddPCR Supermix reaction 
(total volume 20 μl). The final concentrations of the primers and the probe were 900 nM and 500 nM, 
respectively. The following primers and probes were used for discriminating the expression of the R173W 
and the WT TNNT2 alleles; Fw: GAGGAGGAGAACAGGAG and Rv: GCATCATGTTGGACAAAGCC. 
wt-probe: [FAM]AGGATGAGGCCCGGAAGAAGA[BHQ] and mt-probe 
[HEX]AGGATGAGGCCTGGAAGAAGA[BHQ]. Droplet formation was carried out using a QX100 
droplet generator. A rubber gasket is placed over the cartridge and loaded into the droplet generator. The 
emulsion (35 μL in volume) was then slowly transferred using a multichannel pipette to a 96-Well twintec™ 
PCR Plates (Eppendorf). The plate was heat-sealed with foil and the emulsion was cycled to end point per 
the manufacturer's protocol with an annealing temperature at 61°C. Finally, the samples were analyzed 
using a BioRad QX100 reader. The expression of TNNT2 was quantified by Real-Time qPCR (Applied 
Biosystems) using a custom TaqMan probe designed to detect the wild type transcript after TALEN-
mediated KO (Fw: AGACGCCTCCAGGATCTGT, Rv: GCTTCTTCCTGCTCCTCCTC, Probe: 
[FAM]CAGACATGGTCTCTGCTCTCCCTC[BHQ]. 
 
TALEN off-target detection.  
Genomic DNA was extracted from genome edited iPSC clones using the DNeasy Blood & Tissue Kit 
(Qiagen). The potential TALEN off-target sites were predicted in silico based on sequence homology using 







 DOI: 10.1161/CIRCRESAHA.116.309948    6 
the bioinformatics tool PROGNOS.15 The primers designed by PROGNOS were used to amplify the 
genomic regions of putative off-target sites by PCR. The PCR products were analyzed by Sanger 
sequencing.  
 
ChIP-seq analysis.  
The raw Fastq files of ChIP-seq were aligned to human genome (hg19) by TMAP 
(https://github.com/iontorrent/TS/tree/master/Analysis/TMAP), and then all duplicate reads aligned to 
same loci were removed.16 Peak calling was applied by HOMER,17 and the parameters are: style “factor”, 
genome “hg19”, fold-change cutoff 4.0 of DNA input, fold-change cutoff of peak calling 2.0, and p-value 
cutoff 0.0001. Peaks were annotated by HOMER, and the nearest genes were assigned as the genes of the 
peaks. All sequences around coding promoters (upstream 400 bp, downstream 100 bp) were extracted and 
motif enrichment analysis was performed using HOMER. Then KEGG enrichment analysis was performed 
using the GeneAnswers package (http://www.bioconductor.org/packages/release/bioc/html/GeneAnswers. 
html), and adjusted p-value cutoff was 0.1. All alignment bam files were processed by IGVTools, and 
loaded to IGV genome browser18 for the visualization of specific genes, all tracks normalized to 1 million 
reads. 
 
Whole-cell patch-clamp recordings.  
Contracting monolayer iPSC-CMs were enzymatically dispersed (Accutase, Sigma) and attached to 
Matrigel-coated glass coverslips (Warner, USA) for whole-cell patch clamp recordings. These recordings 
were conducted using an EPC-10 patch clamp amplifier (HEKA, Germany). 3-4 MΩ glass pipettes were 
prepared using thin-wall borosilicate glass (A-M System, USA) with a micropipette puller (Sutter 
Instrument, P-97, USA). Action potentials (APs) were recorded from iPSC-CMs suffused with Tyrode’s 
solution at 37oC. The Tyrode’s solution consisted of NaCl (140 mM), KCl (5.4 mM), CaCl2 (1.8 mM), 
MgCl2 (1 mM), HEPES (10 mM), and glucose (10 mM); pH was adjusted to 7.4 with NaOH. The pipette 
solution consisted of KCl (120 mM), MgCl2 (1 mM), Mg-ATP (3 mM), HEPES (10 mM), and EGTA (10 
mM); pH was adjusted to 7.2 with KOH. Data were acquired using PatchMaster software (HEKA, 
Germany) and digitized at 1.0 kHz. Data were analyzed using a custom-written MATLAB program. 
 
Statistical analysis.  
Unpaired two-tailed Student’s t tests were used to determine the significance between two groups, assuming 
significance at P < 0.05. The one-way analysis of variance (ANOVA) was used to determine whether there 
are any statistically significant differences among the means of three or more groups, with P < 0.05 
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RESULTS 
 
Design, construction, and characterization of TALEN constructs. 
 
We selected 88 genes associated with cardiomyopathies and congenital heart diseases (Figure 1a 
and Online Table I), including genes implicated in syndromes for which clinical diagnosis may be 
challenging, such as CHARGE syndrome (chromodomain helicase DNA binding protein 7 (CHD7) 
mutation), Leigh syndrome (SURF1 mutations), Holt-Oram syndrome (TBX5 mutations), Noonan 
syndrome, LEOPARD syndrome, Raf-1 proto-oncogene, serine/threonine kinase (RAF1) and protein 
tyrosine phosphatase, non-receptor type 11 (PTPN11) mutations. To knock out these genes in the human 
genome, we designed TALENs that target sequences located around the start codon, ATG, of each gene 
(Figure 1b). We constructed one TALEN pair construct for each gene using a library of pre-assembled 
tetramers/trimers through a five-piece subcloning ligation.12 The details of the TALEN design for each gene 
and the respective target site are shown in Online Table I. To validate the genome editing activities of the 
TALEN library in human iPSCs, we quantified the level of NHEJ using the SMRT technology.14 Every 
TALEN pair tested was active and efficiently induced small deletions, insertions, or both at the target sites 
(Online Table II). The individual TALEN pairs induced mutations with a frequency ranging from 0.5% to 
50% (Figure 1c), and the majority of the TALEN-mediated NHEJ outcomes were deletions of variable 
lengths within the spacer region, while insertion mutations were only observed in a few instances (Online 
Table II).  
 
To illustrate the general utility of the TALEN-mediated NHEJ technique, we next targeted six 
individual genes (TNNT2, TBX5, lamin A/C (LMNA/C), myosin, heavy chain 7, cardiac muscle, beta 
(MYH7), ankyrin repeat domain 1 (cardiac muscle) (ANKRD1), and NK2 homeobox 5 (NKX2.5)) in human 
iPSCs. After TALEN transfection and FACS sorting, we screened single cell-derived clones for NHEJ 
events. We observed that the targeted loci were disrupted at high efficiency, with indels occurring in 33% 
to 100% of the clones screened (Table 1). These results indicate that all of our TALEN constructs are highly 
active and can be used for gene KO experiments. 
 
Targeted disruption of the cardiac troponin T gene causes sarcomere disassembly. 
 
 Mutations associated with cardiomyopathies are commonly inherited in an autosomal dominant 
manner. Mutant proteins are thought to act through a dominant-negative mode that either interfere with 
normal function or assume a new function. In some instances, the mutant allele is inactivated, resulting in 
haploinsufficiency whereby a single functional copy of the gene is insufficient to maintain the normal 
phenotype. Although mutations in the cardiac troponin T (TNNT2) gene are commonly implicated in 
familial HCM, distinct mutations can also lead to DCM.19 To address whether haploinsufficiency of TNNT2 
is responsible for HCM or DCM, we ablated either one or both TNNT2 alleles in human iPSCs by TALEN-
mediated gene KO in a single round of TALEN targeting. We generated both monoallelic (heterozygous) 
KO (TNNT2+/-) and biallelic (homozygous) KO (TNNT2-/-) iPSC lines (Figure 2a). These TNNT2-KO iPSC 
lines retained their pluripotency as assessed by immunostainining and gene expression assays of 
pluripotency markers (Online Figure I). Upon differentiation, the cardiac Troponin T protein (cTnT) was 
not detected in TNNT2-/- iPSC-CMs, while comparable levels of cTnT were observed in wild-type and 
TNNT2+/- iPSC-CMs (Figure 2b). At the mRNA level, TNNT2+/- iPSC-CMs had reduced expression of the 
non-targeted transcript compared to the parental iPSC-CMs (Figure 2c), suggesting that the cTnT protein 
levels are not regulated at the transcription level. Most likely a post-transcriptional mechanism, such as an 
increase in ribosome translational kinetics or lower protein turnover rates, is responsible for the comparable 
levels of cTnT protein expression in the TNNT2+/- and WT iPSC-CMs. At the functional level, we observed 
that TNNT2-/- iPSC-CMs displayed severe sarcomeric disarray (Figure 2d) and exhibited impaired 
intracellular Ca2+ cycling (Online Figure II). In contrast, TNNT2+/- iPSC-CMs showed no functional or 
structural abnormalities, suggesting that one TNNT2 allele is sufficient to maintain normal cTnT protein 
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expression and cardiac myocyte structure and function (Figure 2 and Online Figure II). These results 
suggest that haploinsufficiency is unlikely to explain the pathogenesis of cardiomyopathies associated with 
TNNT2 mutations. 
 
Phenotypic rescue of DCM by targeted allelic-specific KO in vitro. 
 
To test this hypothesis, we next disrupted the starting codon of TNNT2 gene in a patient-specific 
iPSC line harboring a missense mutation in exon 12 of the TNNT2 gene (NM_001001430.2: c.517 C>T; 
p.R173W) (Figure 3a).20 We screened the TALEN-targeted clones for NHEJ events, and identified an iPSC 
clone with a disruption of the starting codon of the mutant TNNT2 p.R173W allele (hereafter referred to as 
DCM-KO) and without any detectable off-target mutations  (Figure 3a and Online Table III). This isogenic 
KO line retained pluripotency as assessed by both immunostaining and gene expression assays of 
pluripotency markers (Online Figure III). We differentiated the isogenic iPSC lines to iPSC-CMs and 
observed that the DCM-KO iPSC-CMs had undetectable (<10%) mRNA expression of the mutant TNNT2 
allele when compared to the parental line, consistent with the activation of the nonsense-mediated mRNA 
decay mechanism following the NHEJ repair process (Online Figure IV).21 In addition, we observed that 
the loss of the mutant allele ameliorated the DCM phenotype in vitro, including sarcomere disarray (Figure 
3b-c) and Ca+2 cycling parameters (Figure 3d-e). Taken together, these data suggest that the TNNT2 
p.R173W is a dominant negative mutation, and allelic-specific KO could ameliorate the DCM phenotype 
in vitro. 
 
Modeling Holt-Oram syndrome in vitro. 
 
Cardiac development is a critical and complex embryologic process requiring the integration of cell 
commitment, growth, looping, septation, and chamber specification.22 Multiple transcription factors, 
including NKX2.5, GATA4, and TBX5 play important roles in cardiac development, and genetic studies 
have implicated dominant mutations in these genes in human CHD. TBX5 is a T-box-containing 
transcription factor, which like other T-box family members, has been implicated in vertebrate tissue 
patterning and differentiation.23-25 TBX5 represents one of the few genes which, when mutated, is known to 
cause CHD.23 TBX5 haploinsufficiency is associated with Holt-Oram syndrome (HOS), a congenital 
disorder characterized by structural cardiac and limb abnormalities.26 Tbx5 heterozygous null (Tbx5-/+) mice 
recapitulated the CHD seen in HOS patients, whereas homozygous null mice (Tbx5-/-) are growth arrested 
at E9.0 and die in utero by E10.5 due to severe heart defects.26 Although the expression of many genes such 
as NPPA, GJA5, IRX4, MYL2, GATA4, NKX2.5, and HEY2 was reduced in TBX5-null hearts,26 little is 
known about their downstream targets and hence the molecular basis of HOS is poorly understood. 
 
As a proof-of-principle experiment for creating CHD models, we generated a human cell-based 
HOS in vitro model by utilizing TALEN-mediated NHEJ to knockout the TBX5 gene in iPSCs. In humans, 
TBX5 is highly regulated through alternative splicing and several transcript variants encoding different 
isoforms have been described for TBX5. Based on RNA-seq data of iPSC-CMs, the transcript variant 4 
(NM_181486) is the predominant TBX5 isoform that is expressed in iPSC-CMs. Of note, the presence of 
this transcript was also reported in the initial identification of TBX5 as the HOS gene.27 The isoforms 1 
(NM_000192) and 3 (NM_080717) were also detected in iPSC-CMs, albeit at very low levels (Online 
Figure V). Hence, we designed a TALEN pair and targeted the starting codon at exon 1 of the major isoform 
4 and isoform 1 (Figure 4a). We identified an iPSC clone carrying a homozygous deletion, which resulted 
in frameshift mutations and an early termination of the TBX5 gene (hereafter referred to as TBX5-KO) 
(Figure 4b). The isogenic TBX5-KO iPSCs retained their pluripotency as assessed by immunostaining and 
gene expression assays of pluripotency markers (Online Figure VI). In order to check the specificity, we 
assessed potential off-target cutting sites in the edited clones using in silico prediction algorithms and did 
not detect any mutations in the 25 most likely off-target sites, suggesting a high specificity of the TBX5 
TALEN pair (Online Table IV). We then differentiated the isogenic iPSC clones into iPSC-CMs and 
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confirmed that the TBX5 (isoforms 1 and 4) was not expressed at the protein level (Figure 4c). The directed 
differentiation protocol yielded cultures enriched (70%–85%) in cTnT (+) beating iPSC-CMs in both WT 
and TBX5-KO iPSC lines at day 15 post-differentiation (Online Figure VII) that displayed a typical 
sarcomeric morphology (Figure 4b). As HOS is associated with electrophysiological abnormalities,26,28 we 
next characterized the action potential (APs) of the isogenic iPSC-CMs. Both TBX5-KO and WT iPSC-
CMs displayed typical AP morphologies, including ventricular-, atrial-, and nodal-like subtypes (Figure 4d 
and Online Table V). However, we observed that 35% of TBX5-KO iPSC-CMs exhibited marked 
proarrhythmic activity characterized by the development of depolarizing humps during phase 2 and 3 of 
the action AP that resemble early after-depolarizations (EADs) when compared to the parental iPSC-CMs 
(Figure 4e).  
 
Identification of novel TBX5 target genes. 
 
To identify downstream targets and TBX5-dependent molecular networks, we next performed 
chromatin immunoprecipitation coupled to massively parallel sequencing (ChIP-seq) together with RNA-
seq analyses. RNA-seq analysis of isogenic iPSC-CMs revealed profound changes in global gene 
expression. We identified 349 up-regulated and 645 down-regulated gene transcripts in TBX5-KO when 
compared to the parental WT iPSC-CMs at a false discovery rate (FDR) of 5%. Analysis of a representative 
subset of these genes by qRT-PCR in independent experiments validated our findings (Online Figure VIII). 
Of note, the most significant down-regulated gene was NPPA (Figure 5a and Figure 5b), a known direct 
target of TBX5.29 As available antibodies for TBX5 are not suitable for genome-wide ChIP-seq, we used a 
lentivirus to express a FLAG-tagged TBX5 in WT iPSC-CMs. We performed FLAG-mediated ChIP-seq 
to define the binding sites of TBX5 genome-wide. We identified 4,518 TBX5-bound peaks that were 
significantly enriched in the TBX5-FLAG sample compared with the control sample (FDR < 0.01). To 
validate the ChIP-seq peaks, we next performed de novo motif analysis to investigate the predominant 
motifs enriched in TBX5 binding sites. As expected, the identified peaks were highly enriched for the 
previously experimentally discovered motif of TBX5 (Online Figure XI).29  
 
Next, to define the direct TBX5 gene regulatory networks, we correlated TBX5 binding and TBX5-
mediated gene regulation by combining the gene set containing TBX5 peaks with the genes differentially 
expressed between the TBX5KO and WT iPSC-CMs. We annotated the TBX5-bound regions to the nearest 
transcription-starting site (TSS) and identified 341 candidate TBX5 direct target genes (118 up- and 223 
down-regulated genes) (Figure 5c). To further refine the identification of TBX5 target genes, we analyzed 
the 223 downregulated gene set andrevealed important genes associated with cardiac myocyte function, 
such as cardiac myosin-binding protein C (MYBPC3), titin (TTN), calsequestrin (CASQ2), natriuretic 
peptide type A (NPPA), connexin 43 (GJA5), and sodium voltage-gated channel alpha subunit 5 (SCN5A). 
Remarkably, we found that 40% of the TBX5 candidate target genes were enriched in unexpected pathways 
ostensibly unrelated to processes associated with heart function. These pathways included extracellular 
matrix (ECM)-receptor interaction, focal adhesion, and protein digestion and absorption (Figure 5d). We 
found that the TBX5 was bound to promoter regions of key components of the embryonic provisional 
matrix, including perlecan (HSPG2),30 fibronectin (FN1),31,32 fibulin-1 (FBLN1),33 collagen XIV 
(COL14A3),34 versican (VCAN),35-37 and versican-degrading protease ADMTS9.34 These ECM components 
play essential roles in cardiac development and are indispensable for normal heart development by 
regulating heart tube segmentation, chamber specification, endocardial cushion formation, interventricular 
septal formation, and cardiac myocyte differentiation.38 Taken together, these data suggest that genes 
encoding embryonic ECM components are direct TBX5 targets and represent potential novel candidate 
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DISCUSSION 
 
In the past decade, advances in cardiovascular genetics have uncovered a plethora of genes 
associated with inherited cardiomyopathies. Delineating the role of cardiomyopathy-associated genes and 
variants could provide a better understanding to the underlying pathogenic mechanisms, and provide 
potential targets for therapeutic interventions. The advent of new technologies, including iPSC and genome 
editing with designer nucleases, has provided an unprecedented opportunity for disease modeling in vitro. 
Since the development of a highly active TALEN architecture39 and simplified engineering platforms12, 
TALEN-mediated genome editing has been demonstrated in diverse cell types, including pluripotent stem 
cells.12,40-42 The relatively unconstrained target site requirements43 and the high degree of specificity of 
TALENs, provide a valuable tool for genome editing.  
 
In principle, a TALEN pair can be targeted to any site in a genome, allowing more freedom and 
flexibility in target site selection with minimal off-target mutagenesis when compared to newer 
technologies such as CRISPR/Cas9.44-46 In this study, we designed, constructed, and validated TALEN 
vectors as an effective tool for gene KO in human iPSCs. The cTAL panel consists of 88 TALEN pairs that 
are designed to knockout genes that are associated with cardiomyopathies and CHD. Every TALEN pair 
was individually validated in human iPSCs and found to be active at the targeted locus. Furthermore, we 
have established that the target sites needs to be carefully chosen as TALEN pairs that target either the start 
codon (ATG) or regions immediately after are more effective in disrupting the open reading frame of the 
targeted gene. In contrast, indels at the 5-end UTR are inefficient in modifying the open reading frame. It 
should also be noted that even though the start codon is deleted, there might be a downstream translation 
starting sites that could function alternatively.  
 
An important issue in cardiovascular genetics is determining whether putative mutations are 
causative of the disease, and establishing causality for putative disease causing variants is becoming 
increasingly clinically relevant. As a proof-of-concept, we showed that the DCM phenotype in iPSC-CMs 
was ameliorated by selectively disrupting the starting codon of the DCM-causing TNNT2 allele in a patient-
specific iPSCs. In addition, using a similar strategy, we created a CHD model of HOS in vitro and identified 
a number of novel genes that are associated with TBX5 haploinsufficiency, providing an entry point to 
understanding the complex phenotypes caused by TBX5 haploinsufficiency and the pathogenesis of HOS. 
Taken together, these results demonstrated that TALEN-mediated gene KO strategies in iPSCs could be 
used to interrogate disease-causing mutations in a wide range of diseases and cell types as well as to model 
complex diseases in vitro. 
 
 In summary, combining iPSC and genome editing technologies holds great promise for advancing 
fundamental knowledge of the pathogenesis of inherited cardiomyopathies and CHD. The methods, 
strategies, and constructs developed in this study provide a validated, readily available resource for 
cardiovascular research that simplifies the custom generation of iPSC knock-out cell lines, and will 
therefore have a broad applicability for the generation of iPSC-based disease models and functional studies.  
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FIGURE LEGENDS 
 
Figure 1. The cTAL-KO panel. a) Genes associated with cardiomyopathies and congenital heart diseases 
included in the panel. b) Schematic representation of the gene KO strategy. c) Frequency distribution of the 
TALEN-mediated mutagenesis in human iPSCs as assessed by single-molecule real-time (SMRT) 
technology. The DNA fragments surrounding the TALEN target site was amplified and sequenced by 
PacBio RS as described in the “Materials and Methods” section. The mutation frequency of each TALEN 
pair was calculated as follows: mutation frequency (%) = number of reads containing a different length of 
deletion mutations/total number of reads harboring deletion mutation in the target locus × 100. HCM, 
hypertrophic cardiomyopathy; DCM, dilated cardiomyopathy; LVNC, left ventricular non-compaction; 
ARVD, arrhythmogenic right ventricular dysplasia; RC, restrictive cardiomyopathy. 
 
Figure 2. Generation of TNNT2 knockout iPSC clones. a) Schematic representation of TNNT2 gene 
structure. TALENs were designed to target the translation initiation site (ATG) at exon 2 of TNNT2 gene. 
Boxes indicate the TALEN binding sites. Deletions in the two alleles of each clone are indicated. b) 
Expression of cardiac troponin-T protein in isogenic wild-type (WT), heterozygous (TNNT2+/-), and 
homozygous (TNNT2-/-) knockout iPSC-CMs. Representative blots of the protein expression and 
densitometric analysis of TNNT2 protein expression levels normalized to α-sarcomeric actinin (ACTN2) 
in isogenic iPSC-CMs as indicated. Data represent mean ± SEM of three independent differentiation 
experiments, * P < 0.05. c) mRNA expression of the WT allele in the TNNT2+/- and WT iPSC lines. A 
qPCR probe was designed to distinguish between the non-edited (WT) and the TALEN-mutated mRNA of 
the TNNT2+/- iPSC-CMs. Gene expression levels were normalized to cardiac specific gene ACTN2. Data 
represent mean ± SEM of three independent differentiation experiments, *P < 0.05. d) Representative 
immunofluorescence images of iPSC-CMs stained for the cardiac myocyte-specific markers cardiac 
troponin-T (TNNT2, red) and α-sarcomeric actinin (ACTN2, green). DNA was counterstained with DAPI 
(blue). Scale bar = 20 μm. All the assays were performed at 30 days post-differentiation with one isogenic 
pair.  
 
Figure 3. TNNT2 R173W is a dominant, causal DCM mutation. a) Generation of allelic-specific TNNT2 
knockout iPSC clones. TALENs were designed to target the translation initiation site (ATG) at exon 2 of 
TNNT2 gene. Boxes indicate the TALEN binding sites. The nucleotide in red indicates the missense 
mutation for R173W. A deletion in the TNNT2 allele (R173W) allele is indicated. b) Representative 
immunofluorescence images of iPSC-CMs stained for the cardiac myocyte-specific markers cardiac 
troponin-T (TNNT2, red) and α-sarcomeric actinin (ACTN2, green). DNA was counterstained with DAPI 
(blue). Scale bar = 20 µm. c) Quantification of disorganized sarcomeric staining pattern in WT, isogenic 
DCM, and DCM-KO iPSC-CMs. Data represent mean ± SEM (n=150 iPSC-CMs per iPSC line), *P < 0.05. 
d) Representative Ca2+ transients of iPSC-CMs as indicated. e) Quantification of calcium handling 
parameters in WT, isogenic DCM, and DCM-KO iPSC-CMs. Data represent mean ± SEM (n=30 iPSC-
CMs per line), *P < 0.05. All the assays were performed at 30 days post-differentiation with one isogenic 
pair.   
 
Figure 4. Modeling HOS in human iPSCs. a) Schematic representation of TBX5 gene structure. TALENs 
were designed to target the translation initiation site (ATG) at exon 1 of TBX5 gene. Boxes indicate the 
TALEN binding sites. The TALEN-mediated deletions in the two alleles of the iPSC clone are shown. b) 
Representative immunofluorescence images of iPSC-CMs stained for the cardiac myocyte-specific marker 
cardiac troponin-T (cTnT). DNA was counterstained with DAPI (blue). c) Assessment of TBX5 protein 
expression in isogenic iPSC-CMs by western blot analysis; cTnT was used as a loading control. d) AP 
characterization in isogenic iPSC-CMs. d) TBX5-KO iPSC-CMs exhibit a proarrhythmia phenotype 
manifested as early after-depolarizations (EADs) during phase 2 and 3 of the AP waveform.  
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Figure 5. TBX5 regulates extracellular matrix (ECM) genes in iPSC-CMs. a) Top 20 differentially 
expressed genes between isogenic TBX5-KO and WT iPSC-CMs as assessed by RNA-seq. Blue bars 
represent up-regulated genes; red bars represent down-regulated genes. b) Representative browser tracks 
of NPPA gene expression in isogenic WT and TBX5-KO iPSC-CMs, and ChIP-seq footprint shows that 
TBX5 binds to the TSS of the NPPA gene. c) Intersection with ChiP-seq and transcriptional profiling 
identified 341 candidate TBX5 direct target genes. Blue circles represent up-regulated genes and red circles 
represent down-regulated genes (TBX5KO/WT); green circle represent TBX5-bound regions. d) A 
significant enrichment of extracellular matrix (ECM) components were observed in TBX5 direct target 
genes. The extracellular matrix (ECM)-receptor interaction and focal adhesion were the two most 
significant gene-sets over-represented among the 223 down-regulated (TBX5KO/WT) TBX5-bound genes. 
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 NOVELTY AND SIGNIFICANCE 
 
What Is Known? 
 
 Advances in cardiovascular genetics have uncovered many genes associated with inherited 
cardiomyopathies. 
 
 The use of human induced pluripotent stem cell-derived cardiac myocytes (iPSC-CMs) provides an 




What New Information Does This Article Contribute? 
 
 Transcription activator–like effector nucleases (TALENs) facilitate gene knockout (KO) with high 
efficiency, precision and accuracy. 
 
 Successful creation of human-based KO cell models in vitro by combining genome editing and iPSC-
CM technologies.  
 
 TALEN-mediated allele-specific KO ameliorate dilated cardiomyopathy (DCM)-associated 
phenotypes in iPSC-CMs in vitro. 
 
 Modeling Holt-Oram syndrome (HOS) in iPSC-CMs in vitro uncovered novel genes and pathways 
regulated by TBX5. 
 
The advent of human iPSC technology and an increasingly refined capacity to differentiate iPSCs into 
disease-relevant cell types, such as iPSC-CMs, provide an unprecedented opportunity for the generation of 
human cell-based disease models to study genetic cardiomyopathies. Genome editing can be used to change 
the DNA in iPSCs to aid the understanding of the biology of cardiomyopathy-associated genes and how 
they work. We can now make changes (or ‘edits’) to the DNA in specific location in the genome using an 
‘engineered nuclease’, an enzyme that can be tailored to cut the genome in a specific place. Here we 
harnessed this technology to generate iPSC-based KO models of genetic cardiomyopathies to study the 
underlying pathogenic phenotypes and mechanisms, as well as to genetically correct the disease in vitro. 
Implementation of this unique and clinically relevant model system presents a significant advantage in 
cardiovascular research as it can circumvent complications in translating data from models across different 
species and biological characteristics. Ultimately, a better understanding of molecular mechanism(s) of 
genetic cardiomyopathies could provide opportunities for diagnosis and prognosis as well as enable the 
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TNNT2 13.1 22 11 50.0 
LMNA 12.5 12 8 66.7 
MYH7 50.2 24 24 100 
ANKRD1 6.7 24 11 45.8 
TBX5 48.5 32 26 81.3 
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Genotyping iPSC clones. Genomic DNA was extracted from iPSC clones using the DNeasy 
Blood & Tissue Kit (Qiagen). Genotyping at the TALEN target site was then performed for each 
sample by PCR amplification using the PrimeSTAR GXL DNA Polymerase (Clonetech) with a 
primer pair designed to amplify a ~500 bp fragment surrounding the TALEN targeted site. The 
PCR amplicons were purified with the QIAquick PCR Purification Kit (Qiagen) and blunt-end 
cloned with the StrataClone Blunt PCR Cloning Kit (Stratagene) per manufacturer’s protocol. 
The cloning reactions mixture (2 ul) was transformed into competent cells and plated on agar 
containing ampicillin (50 ug/ml) treated with 40 µl of 2% X-gal for blue-white color screening.  
After overnight incubation, white colonies were picked and grown for 16 hr at 37°C in 
ampicillin-containing LB broth. Plasmid DNA was extracted using the QIAprep Spin Miniprep 
Kit (Qiagen) and digested with EcoRI (Fermentas) to identify PCR insert-containing plasmids. 
Ten putative insert-containing plasmids were sequenced by Sanger to confirm presence of the 
mutant allele(s).  
 
Immunocytochemistry. iPSCs were cultured on Matrigel-coated coverslips, fixed in 4% 
paraformaldehyde (10 min at room temperature), and permeabilized in blocking/permeabilization 
buffer (2% BSA / 2% FBS / 0.01 % Triton-X in PBS) for 45 min at room temperature and 
incubated with the indicated primary antibodies re-suspended in PBS / 2% BSA / 2% FBS. 
Following an overnight incubation at 4°C, the cells were washed three times in PBS-0.1% 
Tween-20 and incubated with an Alexa-conjugated secondary antibody (Life Technologies) 
diluted in blocking/permeabilization buffer (1:750). Finally, after washing three times in PBS / 
0.1% Tween-20, the cells were counterstained with DAPI (Life Technologies). The following 
antibodies were used: mouse monoclonal anti-OCT4 (1:100, Santa Cruz; sc-5279), goat 
polyclonal anti-NANOG (1:100, R&D systems; AF1997), mouse monoclonal anti-SOX2 (1:100, 
R&D systems; MAB2018), and mouse monoclonal anti-SSEA-4 (1:100, R&D systems; 
MAB1435). Similarly, iPSC-CMs were dissociated and cultured on Matrigel-coated coverslips 
for 4-5 days, then fixed in 4% paraformaldehyde and permeabilized in blocking/permeabilization 
buffer for 45 min. The cells were incubated with Alexa-conjugated primary antibodies overnight 
at 4°C, washed in PBS, and counterstained with DAPI. The following primary antibodies were 
used: mouse monoclonal anti-cardiac troponin T (1:200, Thermo Fisher Scientific; MS-295-P1) 
and mouse monoclonal anti-alpha actinin (1:200, Abcam; ab9465). For double staining 
experiments, the monoclonal antibodies were fluorescently labeled using the Zenon antibody 
labeling kit (Life Technologies), then applied directly to the samples. Immunofluorescence 
images were acquired using a Nikon epifluorescence microscope.  
 
Western blot analysis. Cells were lysed in RIPA buffer (Sigma) supplemented with protease 
and phosphatase inhibitors (Roche) for 30 min on ice. Following lysis, cells were sonicated for 
10 sec and then centrifuged (12,000g) for 10 min at 4°C. The protein concentration of the lysate 
was quantified using the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific) and 30 µg of 
protein lysate was used in SDS polyacrylamide gel electrophoresis and followed by blotting. The 
blots were probed with antibodies against cardiac Troponin T (Thermo Fisher Scientific; MS-
295-P1), alpha-sarcomeric actin (Abcam; ab28052), and TBX5 (Abgent; AP14687a).  
 
Chromatin immunoprecipitation. Differentiated iPSC-CMs (2.5 x107) were infected (MOI = 
1) with a lentivirus expressing a FLAG-epitope tagged TBX5 (TBX5-FLAG in pLX303 was a 
gift from William Hahn; Addgene plasmid # 42563). After seven days, the cells were fixed with 
1% formaldehyde for 10 min to generate protein-protein and protein-DNA crosslinks. The cross-
linking reaction was stopped by adding 2.5 M glycine and incubated for 10 min at room 
temperature, washed twice with cold PBS. Cells were then scraped, mechanically sheared using 
sonication, and centrifuged at 10,000g for 30 min at 4°C. The supernatant was incubated 
overnight at 4°C with 10 µl of either anti-FLAG (F1804, Sigma-Aldrich) or mouse IgG (sc-2027, 
Santa Cruz Biotechnology) that were covalently conjugated to Dynabeads® Protein A/G (Life 
Technologies). A small portion of the crosslinked, sheared chromatin was saved and served as 
the ‘Input’ negative control DNA. The next day, the beads were rinsed with sonication buffer (50 
mM Hepes pH 7.9, 140 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% Na-deoxycholate, 
0.1% SDS, 0.5 mM PMSF), high salt buffer (50 mM Hepes pH 7.9, 500 mM NaCl, 1 mM 
EDTA, 1% Triton X-100, 0.1% Na-deoxycholate, 0.1% SDS, 0.5 mM PMSF), and LiCl buffer 
(20 mM Tris, pH 8.0, 1 mM EDTA, 250 mM LiCl, 0.5% NP-40, 0.5% Na-deoxycholate, 0.5 mM 
PMSF). The washed beads were incubated with elution buffer (50 mM Tris, pH 8.0, 1 mM 
EDTA, 1% SDS, 50 mM NaHCO3) for 1 hr at 65oC and then reverse cross-linked by adding 5 M 
NaCl and incubated overnight at 65oC. The immunoprecipitated DNA was treated with Rnase A 
and Proteinase K, and finally purified using the ChIP DNA clean and concentrator kit following 
the manufacturer’s protocol (Zymo Research). Twenty ng of ChIP DNA or ‘input’ DNA was 
used for library preparation using the IonXpress Plus Fragment Library Kit according to the 
manufacturer’s protocol (Publication Number 4473623 Revision B; Life Technologies). Briefly, 
the DNA was end-repaired and purified. The end-repaired DNA was ligated to Ion-compatible 
adapters, followed by nick repair to complete the linkage between barcode adapters and DNA 
inserts. The library was amplified by PCR and purified with two rounds of AMPure® XP 
(Beckam-Coultier) bead capture to size-select fragments for downstream template preparation 
using the automated Ion Chef system. Sequencing was performed using the Ion PI Sequencing 
IC Kit and the Ion PI Chip v2 on the Ion Proton sequencer (Life Technologies).  
 
Lentivirus production. The day prior to transfection, 5x106 HEK293T cells (Life Technologies) 
were plated in 10 cm dish in DMEM media supplemented with 10% FBS. A transfection cocktail 
containing 2 µg FLAG-TBX5 (Addgene #42563) plasmid, 1.5 µg pMD2.G envelope plasmid 
(Addgene #12259), and 0.5 µg psPAX2 packaging plasmid (Addgene #12260) was prepared in 
50 µl serum-free Opti-MEM (Life Technologies) and mixed with 12 µl Lipofectamine 2000 (Life 
Technologies) diluted in 50 µl serum-free Opti-MEM. After 10 min incubation at room 
temperature, the transfection mixture was added to the cells and incubated overnight at 37oC and 
5% CO2. The next day, the media was replaced with serum-free OPTI-MEM and the transfected 
HEK293T cells were cultured for an additional 72 hr, and the supernatant was collected every 24 
hr. The combined virus containing supernatant was centrifuged at 3000g for 15 min to remove 
the cell debris, followed by concentration by PEG-it according to the manufacturer’s protocol 
(System Biosciences). The infectious viral titer in the concentrated supernatant was estimated by 
transfection of HEK293T cells with 10-fold serial dilutions (10−1 to 10−6), followed by 
quantifying the number of FLAG-expressing cells or colonies of cells at 72 hr post-infection. 
 
SNP karyotyping. SNP karyotype analysis was performed on the Illumina’s CytoSNP-850K 
genotyping microarrays, which measure approximately 850,000 SNPs across the genome. All 
genomic DNA was isolated from iPSC clones according to the manufacturer’s protocol (Qiagen). 
Input genomic DNA (500 ng) was processed, hybridized to the array, and scanned on an Illumina 
HiScan according to the manufacturer’s instructions. CNVs were identified using the 
cnvPartition Pluginv.3.2.0 in GenomeStudio (Illumina) by assessing both the B-allele-frequency 
and Log R ratios.  
 
Ca2+ imaging. Dissociated iPSC-CMs were reseeded in Matrigel-coated 8-well Lab Tek II 
chambers (Nalge Nunc International). Cells were recovered for 3 days and were loaded with 5 
µM Fluo-4 AM with 0.02% Pluronic F-127 (Molecular Probes) in Tyrode’s solution for 15 min 
at 37°C, and were washed with Tyrode’s solution afterwards. Ca2+ imaging was conducted using 
a Zeiss LSM 510Meta confocal microscope (Carl Zeiss AG, Göttingen, Germany). Spontaneous 
Ca2+ transients of single beating iPSC-CMs were obtained using a time-lapse line scanning 
recording mode (512 pixels x 1920 lines) under 40X objective (Plan Apochromat, 0.95 NA) at 
37°C, and the raw data was analyzed using customized Interactive Digital Language (IDL) 
script. Ca2+ signal was normalized to the intracellular basal line (F0), and transient amplitude was 
expressed as ΔF/F0. 
 
Validation of RNA-seq data by qPCR Total RNAs were isolated from iPSC-CMs using the 
miRNeasy Mini kit (QIAGEN). 1 µg of RNA was used to synthesize cDNA using the iScript™ 
cDNA Synthesis kit (Bio-Rad). 0.25 µl of the reaction was used to quantify gene expression by 
qPCR using TaqMan probes and TaqMan Universal PCR Master Mix. Expression values were 




ONLINE FIGURE LEGENDS 
Online Figure I. A) Representative immunofluorescence images of isogenic TNNT2-KO iPSC 
colonies stained for the pluripotency-associated markers OCT-4, NANOG, SOX-2 and SSEA-4, 
as indicated. B) Relative mRNA expression of pluripotency-associated genes NANOG, OCT-3/4 
and SOX-2.  Expression levels are expressed relative to the parental iPSC line. Values represent 
mean ± SEM (n=3).  
 
Online Figure II. Intracellular calcium cycling analysis. A) Representative line-scan images 
and spontaneous Ca2+ transients for isogenic wild-type (WT), heterozygous (TNNT2+/), and 
homozygous (TNNT2-/-) knockout iPSC-CMs. B) Comparison of tangential amplitude, time to 
peak, and decay tau of calcium imaging between each isogenic group. Data represents mean ± 
SEM of n = 25 single iPSC-CMs per line. Unpaired two–tailed t–test with **P < 0.01, n.s. = not 
significant. 
 
Online Figure III. A) Representative immunofluorescence images of isogenic DCM-KO iPSC 
colonies stained for the pluripotency-associated markers OCT-4, NANOG, SOX-2, and SSEA-4, 
as indicated. B) Relative mRNA expression of pluripotency-associated genes NANOG, OCT-
3/4, and SOX-2.  Expression levels are expressed relative to the parental iPSC line. Values 
represent mean ± SEM (n=3). C) Digital karyotype analysis of the parental iPSC clone.  
 
Online Figure IV.  A) ddPCR for the TNNT2 R173W mutant and wild-type allelic 
discrimination from the parental- and DCM-KO iPSC-CMs. Green and blue dots represent 
droplets containing the mutant and the wild-type alleles, respectively. Pink line indicates the 
detection threshold. B) Quantification of ddPCR shows the average frequency of the WT and 
mutant alleles in the iPSC-CMs as indicated. Values represent mean ± SEM (n=3). 
 
Online Figure V. RNA-seq analysis of TBX5 gene isoforms in iPSC-CMs derived from the 
indicated iPSC lines generated by the Stanford CVI iPSC Biobank. 
 
Online Figure VI. A) Representative immunofluorescence images of isogenic TBX5-KO iPSC 
colonies stained for the pluripotency-associated markers OCT-4, NANOG, SOX-2 and SSEA-4, 
as indicated. B) Relative mRNA expression of pluripotency-associated genes NANOG, OCT-
3/4, and SOX-2.  Expression levels are expressed relative to the parental iPSC line. Values 
represent mean ± SEM (n=3). c) Digital karyotype analysis of the parental iPSC clone.  
 
Online Figure VII. Quantification of the cardiomyocyte differentiation efficiency. Flow 
cytometry analysis of the differentiation efficiency of isogenic TBX5-KO and parental WT iPSC 
lines at 15 days after differentiation. Representative contour plots of iPSC-CMs immunolabeled 
with isotype control antibody (IgG-Alexa-488) or cardiac troponin T antibody (cTnT-Alexa-488) 
in isogenic iPSC-CMs as indicated.  
 
Online Figure VIII. Validation of RNA-seq data by qPCR. Quantitative real-time PCR of 
selective differentially expressed genes. Gene expressions were normalized to 18s and expressed 
as fold-change relative to parental WT iPSC-CMs. A) Upregulated genes and B) downregulated 
genes from RNA-seq data. Values represent mean ± SEM (n=3). 
 
Online Figure XI.  In vitro TBX5 binding motifs. De novo motif discovery of in vitro motif by 
HOMER using the TBX5 peaks of the ChIP-seq data. Motifs found by de novo discovery were 
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Supplementary Figure 9Online Figure IX 
Online Table I.  Mutagenesis Efficiency of TALEN Pairs in human iPSCs as assessed by single-molecule real 
time (SMRT) technology. NHEJ, Non-homologous end joining. 
Clone ID Gene TALEN Plus Strand Target Sequence NHEJ % 
DC47B, DC48 ABCC9 T AAGAAGAAATGAGCC tttcattttgtggta ACAACATTTCTTCAT A 6% 
DC49B, DC50B ACADS T GGCCGCCGCGCTGCT cgcccgggcctcgggcc CTGCCCGCAGAGGTG A 44.80% 
DC73B, DC74B ACADVL T CGAGCCAGCGGCGCC cggagagattcggag ATGCAGGCGGCTCGG A 42.67% 
DC51, DC52 ACTC1 T GCAGAACCCCCTGAA gctgtgccaagatgtgt GACGACGAGGAGACC A 13.37% 
DC53, DC54 ACTN2 T CGCGCCCCGCCGCAG ccccggccaaccgagcg CCATGAACCAGATAG A 2.82% 
DC59, DC60 ANKRD1 T CCTTCAGCCAACATG atggtactgaaagtagag GAACTGGTATGTAAG A 6.73% 
DC65B, DC66B BAG3 T GAGCGCCGCCACCCA ctcgcccatgatgc AGGTGGCGTCCGGCA A 8.40% 
DC67B, DC68B CALR3 T GCACACCCCCATGGC ccgggctttggtccag CTCTGGGCCATATGC A 3.46% 
DC69, DC70 CASQ2 T GGGAACGAGAAACAA aagttttcccaaatgaag AGAACTCACTTGTTT A 0.23% 
DC71C, DC72B CAV3 T GGATCCCCCCAGCTC tgcgatgatggcagaag AGCACACAGATCTCG A 10.34% 
DC75B, DC76B CHD7 T GGTTTGGAGGAGCCG tgtgttggaagaagatg GCAGATCCAGGAATG A 0.33% 
DC77C, DC78 COX15 T GTCATCAGTATGCAG cgattgctctttccg CCGTTGAGGGCCTTG A 10.21% 
DC79B, DC80 CRYAB T CACACTCACCTAGCC accatggacatcgcc ATCCACCACCCCTGG A 11.49% 
DC81B, DC82B CSRP3 T GACCTTGACCAGATA gtcttcaagatgccaaac TGGGGCGGAGGCGCA A 1.61% 
DC83C, DC84B CTF1 T GAAGGGAGCCGGGAT cagccaggggccagcat GAGCCGGAGGGAGGG A 19.70% 
DC209, DC210 CTNNA3 T GTTTGTGCACAGGCA gcatgtcagctgaa ACACCAATCACATTG A 7.72% 
DC85C, DC86B DES T CACCATGAGCCAGGC ctactcgtccagcc AGCGCGTGTCCTCCT A 33.75% 
DC133, DC134 DMD T ATCGCTGCCTTGATA tacacttttcaaaatgct TTGGTGGGAAGAAGT A 0.25% 
DC135, DC136 DNAJC19 T GGTGAGTGCGGCCTT ccggtcttcttggcgacc TCCGGCCCAGGCCTC A 1.13% 
DC87, DC88 DSC2 T GCCCCGAGCCCTCTC catggaggcagcccgc CCCTCCGGCTCCTGG A 28% 
DC89B, DC90B: DSG2 T GCGGCGGCGGGAGGC ggaggcgagggtgcgat GGCGCGGAGCCCGGG A 1.78% 
DC91B, DC92B DSP T GCCCGCCGACATGAG ctgcaacggaggct CCCACCCGCGGATCA A 4.86% 
DC137, DC138 DTNA T ACACATTGTAACTAT tttgtctcatagaatgat TGAAGATAGTGGGAA A 4.67% 
DC93, DC94 EMD T CCGCCTGAGCCCGCA cccgccatggacaact ACGCAGATCTTTCGG A 49.67% 
DC95, DC96 EYA4 T GAGAAAACCACATGG aagactcccaggattt AAATGAACAATCAGT A 21.71% 
DC139, DC140 FHL1 T CCAGCTACAAGGTGG gcaccatggcggaga AGTTTGACTGCCACT A 5.80% 
DC141, DC142 FHL2 T TGCTGAAAAGCCAGG agtcaaaatgactgagc GCTTTGACTGCCACC A 3.55% 
DC97, DC98 FKTN T CAAAAGACAACCAAG tgagcagcacagacta ATGAGTAGAATCAAT A 2.92% 
DC99, DC100 FXN T GTGGACTCTCGGGCG ccgcgcagtagccggc CTCCTGGCGTCACCC A 6.15% 
DC101, DC102 GATA4 T ATCAGAGCTTGGCCA tggccgccaaccacgggc CGCCCCCCGGTGCCT A 0.49% 
DC103, DC104 GATAD1 T CTGCGCCCGCGGGGG ccgcccgagccggccacc ATGCCGCTGGGCCTG A 5.66% 
DC105, DC106 GLA T ATGCTGTCCGGTCAC cgtgacaatgcagct GAGGAACCCAGAACT A 12.75% 
DC211, DC212 HOPX T GCCCCGCAGCGCGCA gggaccatgtcggcggag ACCGCGAGCGGCCCC A 3% 
DC107, DC108 ILK T CGGCGCCGGGACGCT gctatggacgacattt TCACTCAGTGCCGGG A 5.44% 
DC109, DC110 JAG1 T CCCGAGTGCCCGCGG cgcgcggcgcagcg ATGCGTTCCCCACGG A 7.99% 
DC111, DC112 JPH2 T TGTCAGGGGCTATGA tgagatgagtgggggcc GCTTCGACTTTGATG A 1.56% 
DC113, DC114 JUP T CCTTTGTGCCCCCAG tagccacgatggaggtga TGAACCTGATGGAGC A 0.83% 
DC115B, DC116 LAMA4 T TGAGCTCAGCCTGGC gctcggttctgcct CTGTGGCTCCTCTGG A 4.51% 
DC117, DC118 LAMP2 T CTGCGGGGTCATGGT gtgcttccgcctctt CCCGGTTCCGGGCTC A 12.14% 
DC45&DC46: LMNA T CCGGGACCCCTGCCC cgcgggcagcgctgcca ACCTGCCGGCCATGG A 12.54% 
DC35 & DC36 LMNA T GCCAACCTGCCGGCC atggagaccccgtcccag CGGCGCGCCACCCGC A 18.70% 
DC119, DC120 MYLCD T CGGCAGCTGTTGTGG ggcaccatgcgaggc TTCGGGCCAGGCTTG A 26.77% 
DC121, DC122 MYBPC3 T CGTGCCTGGTGTGAC gtctctcaggatgcctga GCCGGGGAAGAAGCC A 0.69% 
DC123, DC124 MYH6 T CTCTGACCCAGGGGA agcaccaagatgaccg ATGCCCAGATGGCTG A 9.32% 
DC43 & DC44 MYH7 T GGCAGTCTTTGGGGC tgccgccccctacc TGCGCAAGTCAGAGA A 6.08% 
DC41 & DC42 MYH7 T TCGGAGATGGCAGTC tttggggctgccgcccc CTACCTGCGCAAGTC A 50.22% 
DC125, DC126 MYL2 T GCTGGGTCCTTTCCA ccatggtgagtacaaggg CTCCAGGAGGTGATG A 0.51% 
DC127, DC128 MYL3 T GTACTTACAGCCCCC aatggcccccaaaaagc CAGAGCCCAAGAAGG A 7.78% 
DC129, DC130 MYLK2 T CCCTACCTCATGGCG acagaaaatggagcagtt GAGCTGGGAATTCAG A 5.98% 
DC131, DC132 MYOM1 T CCTTCAAGGGGCACA ggatgtctttgccttttt ATCAGAGGTGCCACC A 0.84% 
DC143, DC144 MYOZ2 T AATACTATGATGAAG cagagaaaacagcaa GCAACAGCCATCATG A 1.44% 
DC145, DC146 MYPN T TTGTGACAGCATGCA agacgacagcataga AGCTTCTACTTCCAT A 24.84% 
DC213, DC214 NEBL T GAGGGTCCCTGTATT tgaggatataaaagat GAAACTGAAGAAGAA A 1.27% 
DC147, DC148 NEXN T AGAGCAAACATGAAT gatatttcccaaaag GCTGAGGTAAGTCTC A 11.87% 
DC57B & DC58 NKX2.5 T GAGACTGGCGCTGCC accatgttccccagc CCTGCTCTCACGCCC A 9.40% 
DC149, DC150 PDLIM3 T CAGAGCCCGGTGGGC gggaggaaggcggc ATGCCCCAGACGGTG A 1.19% 
DC151, DC152 PKP2 T CGGTCGCCCCCACCG gccccatggcagcccccg GCGCCCCAGCTGAGT A 4.43% 
DC215, DC216 PLN T TCCTGTCCTGCTGGT atcatggagaaagtcca ATACCTCACTCGCTC A 0.73% 
DC153, DC154 PRKAG2 T CAACTTCTGGTTAGA gttatgggaagcgcggtt ATGGACACCAAGAAG A 4.81% 
DC155, DC156 PSEN1 T CTATACAGTTGCTCC aatgacagagttac CTGCACCGTTGTCCT A 2.31% 
DC157, DC158 PSEN2 T CCAGGTGCTTCCAGA ggcagggctatgctca CATTCATGGCCTCTG A 11.91% 
DC159, DC160 PTPN11 T CGCGGAGCCGGAGGG cgggaggaacatgac ATCGCGGAGGTGAGG A 3.87% 
DC161, DC162 RAF1 T AAGCTGCATCAATGG agcacatacaggga GCTTGGAAGACGATC A 4.06% 
DC163, DC164 RBM20 T CCCGGGCGGGTCTCG ccccgcatggtgctgg CAGCAGCCATGAGCC A 3.60% 
DC165, DC166 RYR2 T GGCCGATGGGGGCGA gggcgaagacgagatcca GTTCCTGCGAACTGT A 0.83% 
DC167, DC168 SCN5A T GAGAAGATGGCAAAC ttcctattacctcggggc ACCAGCAGCTTCCGC A 1.94% 
DC217, DC218 SCO2 T GTTTCCAGGAGCATC agatccatgctgctgct GACTCGGAGCCCCAC A 2.43% 
DC169, DC170 SDHA T CCGGGGCCTGTCGCG gctgctgagcgctcgg CGCCTGGCGCTGGCC A 3.64% 
DC171, DC172 SGCD T GAGTGAAGGGACCAG gtggagatggtgag TAATTCCCGGGAGCG A 0.32% 
DC173, DC174 SLC25A20 T GACAGACGGAGTGAC agacggactgacca TGGCCGACCAGCCAA A 2.21% 
DC219, DC220 SLC25A4 T GAGAGCGTCGAGCTG tcaccatgggtgatca CGCTTGGAGCTTCCT A 7.63% 
DC175, DC176 SURF1 T GGCGGCGGTGGCTGC gttgcagctggggctgcg GGCGGCGGGGCTGGG A 3.87% 
DC177, DC178 SYNE1 T CCGGAGGGACCATGG caacctccagaggggcct CCCGGTGTCCTCGGG A 0.48% 
DC179, DC180 TAZ T GGGAGCGCCGGCCGC gggccgggtgggga TGCCTCTGCACGTGA A 0.91% 
DC181, DC182 TBX1 T GCCAGGATCCCCGGC agggatgcacttca GCACCGTCACCAGGG A 5.24% 
DC183, DC184 TBX20 T GGCCAGGACCGCGTG ctggggaccatggagt TCACGGCGTCCCCCA A 15.26% 
DC61B & DC62 TBX5 T GGGCGCACCATGGCC gacgcagacgagggc TTTGGCCTGGCGCAC A 48.45% 
DC185, DC186 TCAP T GAGGAGTGATCATGG ctacctcagagctgagct GCGAGGTGTCGGAGG A 1.32% 
DC187, DC188 TGFB3 T CCCCCTGGCCTCTCT tcccagctcacacatg AAGATGCACTTGCAA A 13.38% 
DC189, DC190 TMEM43 T CCCACCATGGCCGCG aatgtgagtatccccg GGCCAGCCGGGCCAC A 2.43% 
DC191B, DC192B TMPO T GGGGAGGGGGCTTCG cagatccccgagatgc CGGAGTTCCTGGAAG A 5.05% 
DC193, DC194 TNNC1 T CCTGTGAGCCGCCAG catggatgacatctaca AGGCTGCGGTGAGGG A 7.25% 
DC195, DC196 TNNI3 T CCCGGCCTGAGTCTC agcatggcggatgggtga GTGATGCCCCAAGGC A 1.70% 
DC39 & DC40 TNNT2 T TTGGAGGGAGAGCAG agaccatgtctgaca TAGAAGAGGTGGTGG A 2.79% 
DC37 & DC38 TNNT2 T TTTCTCCTTTTGGAG ggagagcagagacca TGTCTGACATAGAAG A 13.14% 
DC197, DC198 TPM1 T CGCCGCCGCCACCAT ggacgccatcaagaag AAGATGCAGATGCTG A 6.45% 
DC199, DC200 TTN T TTTCAGAGTGCCTAG aaagatgacaactcaag CACCGACGTTTACGC A 0.72% 















































DC203, DC204 TXNRD2 T GGCGGTGGCGCTGCG gggattaggagggcgct TCCGGTGGCGGACGC A 0.57% 
DC205, DC206 VCL T TCGCCGCCCCGCTCG ccgccgcgatgccagtg TTTCATACGCGCACG A 1.25% 
DC207, DC208 ZASP T GCAGAGGCGGCCGCT gacagcaccagcatgtct TACAGTGTGACCCTG A 3.09% 
Online	Table	II.	Frequency	and	position	of	TALEN-mediated	mutagenesis	in	human	iPSCs.	Deletions	and	insertions	of	the	top	5	variants	are	shown.				ABCC9																												Mutations	in	134	of	2738	sequences	≈	4.9% 
AGAAGAAATGAGCCTTTCATTTTGTGGTAACAACATTTCTTCATATAATATCAACGATGGTGTACTACAAAATTCCTGCTTTGTGGAT  WT 
AGAAGAAATGAGCCTTTCATTTTGTGGTAACAACATTTCT----------TCAACGATGGTGTACTACAAAATTCCTGCTTTGTGGAT  Δ10 x15 
AGAAGAAATGAGCCTTTCATTTTGTGGTAACAACATTTCTTC----AATATCAACGATGGTGTACTACAAAATTCCTGCTTTGTGGAT  Δ4 x7 
AGAAGAAATGAGCCTTTCATTTTGTGGTAA---------------------CAACGATGGTGTACTACAAAATTCCTGCTTTGTGGAT  Δ21 x6 
AGAAGAAATGAGCCTTTCATTTTGTGGTAACAAC------------AATATCAACGATGGTGTACTACAAAATTCCTGCTTTGTGGAT  Δ12 x4 
AGAAGAAATGAGCCTTTCATTTTGTGGTAAC---------------AATATCAACGATGGTGTACTACAAAATTCCTGCTTTGTGGAT  Δ15 x4		ACADS																													Mutations	in	888	of	1982	sequences	≈	44.8% 
GGGACTGTGTCTGTCGCCCATGGCCGCCGCGCTGCTCGCCCGGGCCTCGGGCCCTGCCCGCAGAGGTGAGTGCGCTGGGGATCCGTAC  WT 
GGGACTGTGTCTGTCGCCCATGGCCGCCGCGCTGCTCGCC-------CGGGCCCTGCCCGCAGAGGTGAGTGCGCTGGGGATCCGTAC  Δ7 x49 
GGGACTGTGTCTGTCGCCCATGGCCGCCGCGCTGCTC------------------GCCCGCAGAGGTGAGTGCGCTGGGGATCCGTAC  Δ18 x44 
GGGACTGTGTCTGTCGCCCATGGCCGCCGCGCTGCTC-------------GCCCTGCCCGCAGAGGTGAGTGCGCTGGGGATCCGTAC  Δ13 x41 
GGGACTGTGTCTGTCGCCCATGGCCGCCGCG----------------------CTGCCCGCAGAGGTGAGTGCGCTGGGGATCCGTAC  Δ22 x12 
GGGACTGTGTCTGTCGCCCATGGCCGCCGCGCT-----------------GCCCTGCCCGCAGAGGTGAGTGCGCTGGGGATCCGTAC  Δ17 x11 	ACADVL																											Mutations	in	1092	of	2559	sequences	≈	42.7% 
CGCCAGAGCTGGGTCAGAGCTCGAGCCAGCGGCGCCCGGAGAGATTCGGAGATGCAGGCGGCTCGGATGGCCGCGAGCTTGGGGCGGC  WT 
CGCCAGAGCTGGGTCAGAGCTCGAGCCAGCGGCGCC----------CGGAGATGCAGGCGGCTCGGATGGCCGCGAGCTTGGGGCGGC  Δ10 x418 
CGCCAGAGCTGGGTCAGAGCTCGAGCCAGCGGCGCC----------CGGAGATGCAGGCGGCTCGGATGGCCGCGAGCTT-GGGCGGC  Δ11 x45 
CGCCAGAGCTGGGTCAGAGCTCGAGCCAGCGGCGC-----------CGGAGATGCAGGCGGCTCGGATGGCCGCGAGCTTGGGGCGGC  Δ11 x45 
CGCCAGAGCTGGGTCAGAGCTCGAGCCAGCGGCGCCCGGA--------GAGATGCAGGCGGCTCGGATGGCCGCGAGCTTGGGGCGGC  Δ8 x31 
CGCCAGAGCTGGGTCAGAGC-------------------------TCGGAGATGCAGGCGGCTCGGATGGCCGCGAGCTTGGGGCGGC  Δ25 x18 	ACTC1																												Mutations	in	451	of	3372	sequences	≈	13.4% 
CGCCCTCCCCTCCTCAACCTGCAGAACCCCCTGAAGCTGTGCCAAGATGTGTGACGACGAGGAGACCACCGCCCTGGTGTGCGACAAC  WT 
CGCCCTCCCCTCCTCAACCTGCAGAACCCCCTGAAGC----------TGTGTGACGACGAGGAGACCACCGCCCTGGTGTGCGACAAC  Δ10 x77 
CGCCCTCCCCTCCTCAACCTGCAGAACCCCCTGAAGC------------TGTGACGACGAGGAGACCACCGCCCTGGTGTGCGACAAC  Δ12 x12 
CGCCCTCCCCTCCTCAACCTGCAGAACCCCCTGAAGCTGTGCcaaCAAGATGTGTGACGACGAGGAGACCACCGCCCTGGTGTGCGAC  +3 x11 
CGCCCTCCCCTCCTCAACCTGCAGAACCCCCTGAAGCTG---CAAGATGTGTGACGACGAGGAGACCACCGCCCTGGTGTGCGACAAC  Δ3 x10 
CGCCCTCCCCTCCTCAACCTGCAGAACCCCCTG----------AAGATGTGTGACGACGAGGAGACCACCGCCCTGGTGTGCGACAAC  Δ10 x10		ACTN2																												Mutations	in	44	of	1563	sequences	≈	2.8% 
GCCCGTGCGTCCGAGCCCCTCGCGCCCCGCCGCAGCCCCGGCCAACCGAGCGCCATGAACCAGATAGAGCCCGGCGTGCAGTACAACT  WT 
GCCCGTGCGTCCGAGCCCCTCGCGCCCCGCCGCAGCC---------------CCATGAACCAGATAGAGCCCGGCGTGCAGTACAACT  Δ15 x4 
CCCG-------------------/ /--------------------CGAGCGCCATGAACCAGATAGAGCCCGGCGTGCAGTACAACT  Δ94 x2 
GCCCGTGCGTCCGAGCCCCTCGCGCCCCGCCGCAGCCCCG---------GCGCCATGAACCAGATAGAGCCCGGCGTGCAGTACAACT  Δ9 x2 
GCCCGTGCGTCCGAGCCCCTCGCGCCCCGCCGCAGCC--------CCGAGCGCCATGAACCAGATAGAGCCCGGCGTGCAGTACAACT  Δ8 x2 
GCCCGTGCGTCCGAGCCCCTCGCGCCCCGCCGtAGCCCCG---------GCGCCATGAACCAGATAGAGCCCGGCGTGCAGTACAACT  Δ9 (Δ10+1) x2 	
 ANKRD1																											Mutations	in	81	of	1203	sequences	≈	6.7% 
ACAGAAAAACATACAAGACTCCTTCAGCCAACATGATGGTACTGAAAGTAGAGGAACTGGTATGTAAGATGCATTAATTTTATAAAAT  WT 
AGAC-------------------/ /--------------------AGTAGAGGAACTGGTATGTAAGATGCATTAATTTTATAAAAT  Δ211 x9 
ACAGAAAAACATACAAGACTCCTTCAGCCAACATGATG---------GTAGAGGAACTGGTATGTAAGATGCATTAATTTTATAAAAT  Δ9 x6 
ACAGAAAAACATACAAGACTCCTTCAGCCAACATGATGGT---------------ACTGGTATGTAAGATGCATTAATTTTATAAAAT  Δ15 x4 
ACAGAAAAACATACAAGACTCCTTCAGCCAACATGATGGTACTG-AAGTA---GAACTGGTATGTAAGATGCATTAATTTTATAAAAT  Δ4 x2 
ACAGAAAAACATACAAGACTCCTTCAGCCAACATGATGGTACTG-AAGTA---GgACTGGTATGTAAGATGCATTAATTTTATAAAAT  Δ4 (Δ5 +1) x2 	BAG3																													Mutations	in	290	of	3453	sequences	≈	8.4% 
CGGGCAGACCCCAACCCAGCATGAGCGCCGCCACCCACTCGCCCATGATGCAGGTGGCGTCCGGCAACGGTGACCGCGACCCTTTGCC  WT 
CGGGCAGACCCCAACCCAGCATGAGCGCCGCCACCCACTC---------GCAGGTGGCGTCCGGCAACGGTGACCGCGACCCTTTGCC  Δ9 x70 
CGGGCAGACCCCAACCCAGCATGAGCGCCGCCACCCACTC------GATGCAGGTGGCGTCCGGCAACGGTGACCGCGACCCTTTGCC  Δ6 x8 
CGGGCAGACCCCAACCCAGCATGAGCGCCGCCACCCACTCGCC---GtTGCAGGTGGCGTCCGGCAACGGTGACCGCGACCCTTTGCC  Δ3 (Δ4+1) x6 
CGGGCAGACCCCAACCCAGCATGAGCGCCGCCACCCACTCG-----GATGCAGGTGGCGTCCGGCAACGGTGACCGCGACCCTTTGCC  Δ5 x5 
CGGGCAGACCCCAACCCAGCATGAGCGCCGCCACCCACTCGC----------aGTGGCGTCCGGCAACGGTGACCGCGACCCTTTGCC  Δ10 (Δ11+1) x4 
 CALR3																												Mutations	in	96	of	2778	sequences	≈	3.5% 
GGCGGCGACCGGAAGCGCAGTGCACACCCCCATGGCCCGGGCTTTGGTCCAGCTCTGGGCCATATGCATGCTGCGAGTGGCGCTGGCT  WT 
GGCGGCGACCGGAAGCGCAGTGCACACCCCCA------------TGGTCCAGCTCTGGGCCATATGCATGCTGCGAGTGGCGCTGGCT  Δ12 x10 
GGCGGCGACCGGAAGCGCAGTGCACACCCCCATGGCCCG------GGTCCAGCTCTGGGCCATATGCATGCTGCGAGTGGCGCTGGCT  Δ6 x7 
GGCGGCGACCGGAAGCGCAGTGCACACCCCCATGGCCCGGG-------CCAGCTCTGGGCCATATGCATGCTGCGAGTGGCGCTGGCT  Δ7 x5 
GGCGGCGACCGGAAGCGCAGTGCACACCCCCATGGCCCGG-----------GCTCTGGGCCATATGCATGCTGCGAGTGGCGCTGGCT  Δ11 x5 
GGCGGCGACCGGAAGCGCAGTGCACACCCCCATGGCCC------------------GGGCCATATGCATGCTGCGAGTGGCGCTGGCT  Δ18 x5 	CASQ2																												Mutations	in	13	of	5713	sequences	≈	0.2% 
ATTCTGCACACGGCATATTTGGGAACGAGAAACAAAAGTTTTCCCAAATGAAGAGAACTCACTTGTTTATTGTGGGGATTTATTTTCT  WT 
ATTCTGCACACGGCATATTTGGGAACGAGAAAC-AAAGT---------TGAAGAGAACTCACTTGTTTATTGTGGGGATTTATTTTCT  Δ10 x2 
ATTCTGCACACGGCATATTTGGGAACGAGAAACAAAAGTTTTCCCaaatgAAATGAAGAGAACTCACTTGTTTATTGT-GGGATTTAT  +4 (Δ1 +5) x1 
ATTCTGCACACGGCATATTTGGGAACGAGAAACAAAAG-TTTCCCaaatgaAAATGAAGAGAACTCACTTGTTTATTGTGGGGATTTA  +5 (Δ1 +6) x1 
ATTCTGCACACGGCATATTTGGGAACGAGAAACAAAAG-TTTCtCActttgTGAAGtGAACTCACTTGTTTATTGTGGGGATTTATTT  +2 (Δ5 +7) x1 
ATTCTGCACACGGCATATTTGGGAACGAGAAACAAAAG--TTCCCaaatgaAAATGAAGAGAACTCACTTGTTTATTGTGGGGATTTA  +4 (Δ2 +6) x1 
 CAV3																													Mutations	in	465	of	4495	sequences	≈	10.3% 
CAGCTCGGATCTCCTCCTGTGGATCCCCCCAGCTCTGCGATGATGGCAGAAGAGCACACAGATCTCGAGGCCCAGATCGTCAAGGATA  WT 
CAGCTCGGATCTCCTCCTGTGGATCCCCCCAGCTCTGCGATGAT----GcAGAGCACACAGATCTCGAGGCCCAGATCGTCAAGGATA  Δ4 (Δ5 +1) x15 
CAGCTCGGATCTCCTCCTGTGGATCCCCCCAGCTCTGC---GATGGCAGAAGAGCACACAGATCTCGAGGCCCAGATCGTCAAGGATA  Δ3 x14 
CAGCTCGGATCTCCTCCTGTGGAT-CCCCCAGCTCTGCGATGAT----GcAGAGCACACAGATCTCGAGGCCCAGATCGTCAAGGATA  Δ5 (Δ6 +1) x12 
CAGCTCGGATCTCCTCCTGTGGATCCCCCCAGCTCT---------GCAGAAGAGCACACAGATCTCGAGGCCCAGATCGTCAAGGATA  Δ9 x8 
CAGCTCGGATCTCCTCCTGTGGATCCCCCCAGCTCTGCGAT-------GAAGAGCACACAGATCTCGAGGCCCAGATCGTCAAGGATA  Δ7 x7 	CHD7																													Mutations	in	7	of	2146	sequences	≈	0.3% 
CAGGCAAGCTCCTGAGCTGTGGTTTGGAGGAGCCGTGTGTTGGAAGAAGATGGCAGATCCAGGAATGATGAGTCTTTTTGGCGAGGAT  WT 
CAGGCAAGCTCCTGAGCTGTGGTTTG-------------------GAAGATGGCAGATCCAGGAATGATGAGTCTTTTTGGCGAGGAT  Δ19 x3 
CAGGCAAGCTCCTGAGCTGTGGTTTGGAGGAGCCGTGTGTTGGA----------AGATCCAGGAATGATGAGTCTTTTTGGCGAGGAT  Δ10 x2 
CAGGCAAGCTCCTGAGCTGTGGTTTGGAGGAGCCGTGTG------------------TCCAGGAATGATGAGTCTTTTTGGCGAGGAT  Δ18 x1 
CAGGCAAGCTCCTGAGCTGT-GTTTGGAGGAGCCGTGTGTTG---GAAGATGGCAGATCCAGGAATGATGAGTCTTTTTGGCGAGGAT  Δ4 x1 
 COX15																												Mutations	in	322	of	3153	sequences	≈	10.2% 
TGGAAGAGGTGGCTGTTCCCTGTCATCAGTATGCAGCGATTGCTCTTTCCGCCGTTGAGGGCCTTGAAGGGGAGGCAGTATCTGCCGC  WT 
TGGAAGAGGTGGCTGTTCCCTGTCATCAGTATGCAGCGA---------------TTGAGGGCCTTGAAGGGGAGGCAGTATCTGCCGC  Δ15 x13 
TGGAAGAGGTGGCTGTTCCCTGTCATCAGTATGCAG----------------CGTTGAGGGCCTTGAAGGGGAGGCAGTATCTGCCGC  Δ16 x5 
TGGAAGAGGTGGCTGTTCCCTGTCATCAGTATGCAGCGATTG-----aggGCCGTTGAGGGCCTTGAAGGGGAGGCAGTATCTGCCGC  Δ5 (Δ8+3) x4 
TGGAAGAGGTGGCTGTTCCCTGTCATCAGTATGCAGCGATT----cTTCCGCCGTTGAGGGCCTTGAAGGGGAGGCAGTATCTGCCGC  Δ4 (Δ5+1) x4 
TGGAAGAGGTGGCTGTTCCCTGTCATCAGTATGCAGCGAT---TCTTTCCGCCGTTGAGGGCCTTGAAGGGGAGGCAGTATCTGCCGC  Δ3 x4 	CRYAB																												Mutations	in	319	of	2776	sequences	≈	11.5% 
CTGACCAGCCAGCTGACCCCTCACACTCACCTAGCCACCATGGACATCGCCATCCACCACCCCTGGATCCGCCGCCCCTTCTTTCCTT  WT 
CTGACCAGCCAGCTGACCCCTCACACTCACCTAG-------------------CCACCACCCCTGGATCCGCCGCCCCTTCTTTCCTT  Δ19 x26 
CTGACCAGCCAGCTGACCCCTCACACTCACCTA---------------GCCATCCACCACCCCTGGATCCGCCGCCCCTTCTTTCCTT  Δ15 x21 
CTGACCAGCCAGCTGACCCCTCACACTCACCTAGCCA----------------CCACCACCCCTGGATCCGCCGCCCCTTCTTTCCTT  Δ16 x17 
CTGACCAGCCAGCTGACCCCTCACACTCACCTAGCCA------------CCATCCACCACCCCTGGATCCGCCGCCCCTTCTTTCCTT  Δ12 x11 
CTGACCAGCCAGCTGACCCCTCACAC--------------------TCGCCATCCACCACCCCTGGATCCGCCGCCCCTTCTTTCCTT  Δ20 x9 
 CSRP3																												Mutations	in	43	of	2679	sequences	≈	1.6% 
CTTTATGTCCCCTTAGACTTGACCTTGACCAGATAGTCTTCAAGATGCCAAACTGGGGCGGAGGCGCAAAATGTGGAGCCTGTGAAAA  WT 
CTTTATGTCCCCTTAGACTTGACCTTGACCAGATAGTCTcC-----GCCAAACTGGGGCGGAGGCGCAAAATGTGGAGCCTGTGAAAA  Δ5 (Δ6 +1) x3 
CTTTATGTCCCCTTAGACTTGACCTTGACCAGATAGTCTT--------CAAACTGGGGCGGAGGCGCAAAATGTGGAGCCTGTGAAAA  Δ8 x2 
CTTTATGTCCCCTTAGACTTGACCTTGACCAGATA-------------------GGGGCGGAGGCGCAAAATGTGGAGCCTGTGAAAA  Δ19 x2 
CTTTATGTCCCCTTAGACTTGACCTTGACCAGATAGTCTTCAAGAT--------------GAGGCGCAAAATGTGGAGCCTGTGAAAA  Δ14 x1 
CTTTATGTCCCCTTAGACTTGACCTTGACCAGATAGTCTTCAAGActatccGCCAAACTGGGGCGGAGGCGCAAAATGTGGAGCCTGT  +5 (Δ1 +6) x1 	CTF1																													Mutations	in	771	of	3914	sequences	≈	19.7% 
CCCCCTCGAAAGGGGGGCGTGAAGGGAGCCGGGATCAGCCAGGGGCCAGCATGAGCCGGAGGGAGGGAAGTCTGGGTAAGGGGCTGAG  WT 
CCCCCTCGAAAGGGGGGCGTGAAGGGAGCCGGGATCA-------GCCAGCATGAGCCGGAGGGAGGGAAGTCTGGGTAAGGGGCTGAG  Δ7 x253 
CCCCCTCGAAAGGGGGGCGTGAAGGGAGCCGGGAT-----------CAGCATGAGCCGGAGGGAGGGAAGTCTGGGTAAGGGGCTGAG  Δ11 x50 
CCCCCTCGAAAGGGGGGCGTGAAGGGAGCCGGGATCAGCCA---GCCAGCATGAGCCGGAGGGAGGGAAGTCTGGGTAAGGGGCTGAG  Δ3 x42 
CCCCCTCGAAA-GGGGGCGTGAAGGGAGCCGGGATCA-------GCCAGCATGAGCCGGAGGGAGGGAAGTCTGGGTAAGGGGCTGAG  Δ8 x19 
CCCCCTCGAAAGGGGGGCGTGAAGGGAGCCGGGATCAGCCAGG---CAGCATGAGCCGGAGGGAGGGAAGTCTGGGTAAGGGGCTGAG  Δ3 x18 
 CTNNA3																											Mutations	in	230	of	2979	sequences	≈	7.7% 
TTATTAATAAGCATCCTTTTGTGTTTGTGCACAGGCAGCATGTCAGCTGAAACACCAATCACATTGAATATCGATCCTCAGGATCTGC  WT 
TTATTAATAAGCATCCTTTTGTGTTTGTGCACAGG--------CAGCTGAAACACCAATCACATTGAATATCGATCCTCAGGATCTGC  Δ8 x38 
TTATTAATAAGCATCCTTTTGTGTTTGTGCACAGGCAGCA-------TGAAACACCAATCACATTGAATATCGATCCTCAGGATCTGC  Δ7 x28 
TTATTAATAAGCATCCTTTTGTGTTTGTGCACAGGCAGCATG-----TGAAACACCAATCACATTGAATATCGATCCTCAGGATCTGC  Δ5 x5 
TTATTAATAAGCATCCTTTTGTGTTTGTGCACAGGCAG-----CAGCTGAAACACCAATCACATTGAATATCGATCCTCAGGATCTGC  Δ5 x5 
TTATTAATAAGCATCCTTTTGTGTTTGTGCACAG-----------GCTGAAACACCAATCACATTGAATATCGATCCTCAGGATCTGC  Δ11 x5 	DES																														Mutations	in	1056	of	3129	sequences	≈	33.7% 
CCGCCAGCCTCGCCCGCGCCGTCACCATGAGCCAGGCCTACTCGTCCAGCCAGCGCGTGTCCTCCTACCGCCGCACCTTCGGCGGGGC  WT 
CCGCCAGCCTCGCCCGCGCCGTCACCATGAG--------------CCAGCCAGCGCGTGTCCTCCTACCGCCGCACCTTCGGCGGGGC  Δ14 x88 
CCGCCAGCCTCGCCCGCGCCGTCACCATG------------------AGCCAGCGCGTGTCCTCCTACCGCCGCACCTTCGGCGGGGC  Δ18 x70 
CCGCCAGCCTCGCCCGCGCCGTCACCATGAGCCAG-------------GCCAGCGCGTGTCCTCCTACCGCCGCACCTTCGGCGGGGC  Δ13 x27 
CCGCCAGCCTCGCCCGCGCCGTCACCATG------------------AGCCAGCGCGTGTCCTCCTACCGCCGCACCTTCGGCGGGG-  Δ19 x20 
CCGCCAGCCTCGCCCGCGCCGTCACCATGAG--------------CCAGCCAGCGCGTGTCCTCCTACCGCCGCACCTTCGGCGGGG-  Δ15 x18 
 DMD																														Mutations	in	4	of	1589	sequences	≈	0.3% 
AACTTTTACCAGGTTTTTTTTATCGCTGCCTTGATATACACTTTTCAAAATGCTTTGGTGGGAAGAAGTAGAGGACTGTTGTAAGTAC  WT 
AACTTTTACCAGGTTTTTTTTATCGCTGCCTTGATATACA------------CTTTGGTGGGAAGAAGTAGAGGACTGTTGTAAGTAC  Δ12 x2 
AACTTTTACCAGGTTTTTTTTATCGCTGCCTTGATATACACTT-------gGCTTTGGTGGGAAGAAGTAGAGGACTGTTGTAAGTAC  Δ7 (Δ8 +1) x1 
AACTTTTACCAGGTTTTTTTTATCGCTGCCTTGATATACAC------AAATGCTTTGGTGGGAAGAAGTAGAGGACTGTTGTAAGTAC  Δ6 x1 
 DNAJC19																										Mutations	in	42	of	3727	sequences	≈	1.1% 
GGGAGCCCAGCCGGAGCCATGGTGAGTGCGGCCTTCCGGTCTTCTTGGCGACCTCCGGCCCAGGCCTCAACCTCAGCTCCCCGCCTCG  WT 
GGGAGCCCAGCCGGAGCCATGGTGAGT--------------------GCGACCTCCGGCCCAGGCCTCAACCTCAGCTCCCCGCCTCG  Δ20 x6 
GGGAGCCCAGCCGGAGCCATGGTGAGTGCGGCCTTCCGGTC----TGGCGACCTCCGGCCCAGGCCTCAACCTCAGCTCCCCGCCTCG  Δ4 x2 
GGGAGCCCAGCCGGAGCCATGGTGAGTGCGGCCTTCCGGTCTT----GCGACCTCCGGCCCAGGCCTCAACCTCAGCTCCCCGCCTCG  Δ4 x1 
GGGAGCCCAGCCGGAGCCATGGTGAGTGCGGCCTTCCGGT-------------------CCAGGCCTCAACCTCAGCTCCCCGCCTCG  Δ19 x1 
GGGAGCCCAGCCGGAGCCATGGTGAGTGCGGCCTTCCGGT-------------------CCAGGCCTCAACCTCAGCT-CCCGCCTCG  Δ20 x1 	DSC2																													Mutations	in	1200	of	4286	sequences	≈	28% 
CCCGACGCTCGGCCCGCGACCTGCCCCGAGCCCTCTCCATGGAGGCAGCCCGCCCCTCCGGCTCCTGGAACGGAGCCCTCTGCCGGCT  WT 
CCCGACGCTCGGCCCGCGACCTGCCCCGAGCCCTCTCCA--------------------------TGGAACGGAGCCCTCTGCCGGCT  Δ26 x87 
CCCGACGCTCGGCCCGCGACCTGCCCCGAGCCCT---------------------------CTCCTGGAACGGAGCCCTCTGCCGGCT  Δ27 x43 
CCCGACGCTCGGCCCGCGACCTG-CCCGAGCCCTCTCCA--------------------------TGGAACGGAGCCCTCTGCCGGCT  Δ27 x18 
CCCGACGCTCGGCCCGCGACCTGCCCCGAGCCCT---------------------CTCCGGCTCCTGGAACGGAGCCCTCTGCCGGCT  Δ21 x17 
CCCGACGCTCGGCCCGCGACCTGCCCCGAGCCCTCTCCATGGAGgcaGCAGCCCGCCCCTCCGGCTCCTGGAACGGAGCCCTCTGCCG  +3 x14 
 DSG2																														Mutations	in	36	of	2027	sequences	≈	1.8%	
AGGCGGCGGCGCGGAGCGGTGCGGCGGCGGGAGGCGGAGGCGAGGGTGCGATGGCGCGGAGCCCGGGACGCGCGTACGCCCTGCTGCT  WT 
AGGCGGCGGCGCGGAGCGGTGCGGCGGCGGGAGGCGGAG--------GCGATGGCGCGGAGCCCGGGACGCGCGTACGCCCTGCTGCT  Δ8 x3 
AGGCGGCGGCGCGGAGCGGTGCGGCGGCGGGAGGCGGA--------------GGCGCGGAGCCCGGGACGCGCGTACGCCCTGCTGCT  Δ14 x2 
AGGCGGCGGCGCGGAGCGGTGCGGCGGCGGGAG----------------------GCGGAGCCCGGGACGCGCGTACGCCCTGCTGCT  Δ22 x2 
AGGCGGCGGCGCGGAGCGGTGCGGCGGCGGGAGGCGGAGGCGAGG----GATGGCGCGGAGCCCGGGACGCGCGTACGCCCTGCTGCT  Δ4 x1 
AGGCGGCGGCGCGGAGCGGTGCGGCGGCGGGAGGCGGAGGCGAGGtgtacTGCGATGGCGCGGAGCCCGGGACGCGCGTACGCCCTGC  +4 (Δ1 +5) x1 
AGGCGGCGGCGCGGAGCGGTGCGGCGGCGGGAGGCGGAGGCGAG---GCGATGGCGCGGAGCCCGGGACGCGCGTACGCCCTGCTGCT  Δ3 x1 	DSP																														Mutations	in	81	of	1668	sequences	≈	4.9% 
GCGCTGAGCCGCTCTCCCGATTGCCCGCCGACATGAGCTGCAACGGAGGCTCCCACCCGCGGATCAACACTCTGGGCCGCATGATCCG  WT 
GCGCTGAGCCGCTCTCCCGATTGCCCGCCGACATGAGCT---------GCTCCCACCCGCGGATCAACACTCTGGGCCGCATGATCCG  Δ9 x3 
GCGCTGAGCCGCTCTCCCGATTGCCCGCCGACATGA------------GCTCCCACCCGCGGATCAACACTCTGGGCCGCATGATCCG  Δ12 x3 
GCGCTGAGCCGCTCTCCCGATTGCCCGCCGACAT-----------GAGGCTCCCACCCGCGGATCAACACTCTGGGCCGCATGATCCG  Δ11 x3 
GCGCTGAGCCGCTCTCCCGATTGCCCGCCGACATGAGCTGCA------GCTCCCACCCGCGGATCAACACTCTGGGCCGCATGATCCG  Δ6 x2 
GCGCTGAGCCGCTCTCCCGATTGCCCGCCGACATGAGCTGC-------------------------ACACTCTGGGCCGCATGATCCG  Δ25 x2 	DTNA																													Mutations	in	222	of	4749	sequences	≈	4.7% 
CCTCAATAGCGTGAGGATAATACACATTGTAACTATTTTGTCTCATAGAATGATTGAAGATAGTGGGAAAAGAGGAAATACCATGGCA  WT 
CCTCAATAGCGTGAGGATAATACACATTGTAACTATTTTGTCTcataCATAGAATGATTGAAGATAGTGGGAAAAGAGGAAATACCAT  +4 x7 
CCTCAATAGCGTGAGGATAATACACATTGTAACTATTTTGTCtcaTCATAGAATGATTGAAGATAGTGGGAAAAGAGGAAATACCATG  +3 x6 
CCTCAATAGCGTGAGGATAATACACATTGTAACTATTTT--------GAATGATTGAAGATAGTGGGAAAAGAGGAAATACCATGGCA  Δ8 x5 
CCTCAATAGCGTGAGGATAATACACATTGTAACTATTT------------TGATTGAAGATAGTGGGAAAAGAGGAAATACCATGGCA  Δ12 x5 
CCTCAATAGCGTGAGGATAATACACATTGTAACTATT----------------TTGAAGATAGTGGGAAAAGAGGAAATACCATGGCA  Δ16 x4 	EMD																														Mutations	in	1053	of	2120	sequences	≈	49.7% 
GGCCCGGGCCGCCGCCAGGCCTCCGCCTGAGCCCGCACCCGCCATGGACAACTACGCAGATCTTTCGGATACCGAGCTGACCACCTTG  WT 
GGCCCGGGCCGCCGCCAGGCCTCCGCCTGAGCCCGCACC---------------CGCAGATCTTTCGGATACCGAGCTGACCACCTTG  Δ15 x171 
GGCCCGGGCCGCCGCCAGGCCTCCGCCTGAGCCCGC--------------ACTACGCAGATCTTTCGGATACCGAGCTGACCACCTTG  Δ14 x54 
GGCCCGGGCCGCCGCCAGGCCTCCGCCTGAGCCCG-------------CAACTACGCAGATCTTTCGGATACCGAGCTGACCACCTTG  Δ13 x33 
GGCCCGGGCCGCCGCCAGGCCTCCGCCTGAGCC---------------------CGCAGATCTTTCGGATACCGAGCTGACCACCTTG  Δ21 x26 
GGCCCGGGCCGCCGCCAGGCCTCCGCCTGAGCCCGCACCCGC--------------CAGATCTTTCGGATACCGAGCTGACCACCTTG  Δ14 x25 
 EYA4																													Mutations	in	66	of	304	sequences	≈	21.7% 
CTTGGGAGTGGCAGGAGAAGTGAGAAAACCACATGGAAGACTCCCAGGATTTAAATGAACAATCAGTAAGTCTTCATTCTCAGTTTTG  WT 
TCTT--------------------/ /--------------------GATTTAAATGAACAATCAGTAAGTCTTCATTCTCAGTTTTG  Δ197 x5 
CTTGGGAGTGGCAGGAGAAGTGAGAAAACCACATGGAA---------GATTTAAATGAACAATCAGTAAGTCTTCATTCTCAGTTTTG  Δ9 x4 
CTTGGGAGTGGCAGGAGAAGTGAGAAAACCAC----------------ATTTAAATGAACAATCAGTAAGTCTTCATTCTCAGTTTTG  Δ16 x4 
AGAG-----------------------/ /-----------------------AATGAACAATCAGTAAGTCTTCATTCTCAGTTTTG  Δ198 x2 
CTTGGGAGTGGCAGGAGAAGTGAGAAAACCACATGGAAGACT---AGGATTTAAATGAACAATCAGTAAGTCTTCATTCTCAGTTTTG  Δ3 x2 	FHL1																													Mutations	in	196	of	3382	sequences	≈	5.8% 
TGCTTGCCCCCGCAGGTCCCTCCAGCTACAAGGTGGGCACCATGGCGGAGAAGTTTGACTGCCACTACTGCAGGGATCCCTTGCAGGG  WT 
TGCTTGCCCCCGCAGGTCCCTCCAGCTACAAGGTG-----------------------/ /------------------------GGC  Δ241 x6 
GGGA--------------/ /---------------GCACC----------------------------------------TGCAGGG  Δ124 x5 
TGCTTGCCCCCGCAGGTCCCTCCAGCTACAAGGTGGGCACCATG-------------------/ /-------------------GCA  Δ223 x5 
TGCTTGCCCCCGCAGGTCCCTCCAGCTACAAGG------------------------/ /-------------------------TGG  Δ242 x5 
TGCTTGCCCCCGCAGGTCCCTCCAGCTACAA---------------GGAGAAGTTTGACTGCCACTACTGCAGGGATCCCTTGCAGGG  Δ15 x5 	FHL2																													Mutations	in	168	of	4734	sequences	≈	3.5% 
TTCTTTTCTTTTTGATAGGTTGCTGAAAAGCCAGGAGTCAAAATGACTGAGCGCTTTGACTGCCACCATTGCAACGAATCTCTCTTTG  WT 
TTCTTTTCTTTTTGATAGGTTGCTGAAAAGCCAGGAGTCAAAatgATGACTGAGCGCTTTGACTGCCACCATTGCAACGAATCTCTCT  +3 x14 
TTCTTTTCTTTTTGATAGGTTGCTGAAAAGCCAGGAGTCA-----ACTGAGCGCTTTGACTGCCACCATTGCAACGAATCTCTCTTTG  Δ5 x6 
TTCTTTTCTTTTTGATAGGTTGCTGAAAAGCCAGGAGT----------------------/ /----------------------CAA  Δ114 x5 
TTCTTTTCTTTTTGATAGGTTGCTGAAAAGCCAGGAGTCAAA--------------------/ /--------------------GCG  Δ175 x4 
TTCTTTTCTTTTTGATAGGTTGCTGAAAAGCCAGGAGTCAAaatgAATGACTGAGCGCTTTGACTGCCACCATTGCAACGAATCTCTC  +4 x4 	FKTN																													Mutations	in	4	of	137	sequences	≈	2.9% 
ATGAAAACGACTGAGATACTTTCAAAAGACAACCAAGTGAGCAGCACAGACTAATGAGTAGAATCAATAAGAACGTGGTTTTGGCCCT  WT 
ATGAAAACGACTGAGATACTTTCAAAAGACAACCAAGTGAGC----CAGAC-AATGAGT--AATCAATAAGAACGTGGTTTTGG-CCT  Δ8 x1 
ATGAAAACGACTGAGATACTTTCAAAAGACAACCAAGTGAG-----CAGACTAATGAGTAGAATCAATAAGAACGTGGTTTTGGCCCT  Δ5 x1 
ATGAAAACGACTGAGATACTTTCAAAAGACAACCAAGTGAG---------CTAATGAGTAGAATCAATAAGAACGTGGTTTTGGCCCT  Δ9 x1 
ATGAAAACGACTGAGATACTTTC-AAAGACAA-CAAG-----AGCACAGAC--ATGA-TAGAATCAATAAGAACGTGGTTTTGGCCCT  Δ10 x1 	FXN																														Mutations	in	156	of	2537	sequences	≈	6.1% 
GGCGGCAGACCCGGAGCAGCATGTGGACTCTCGGGCGCCGCGCAGTAGCCGGCCTCCTGGCGTCACCCAGCCCGGCCCAGGCCCAGAC  WT 
GGCGGCAGACCCGGAGCAGCATGTGGACTCTCGGGC-----------GCCGGCCTCCTGGCGTCACCCAGCCCGGCCCAGGCCCAGAC  Δ11 x7 
GGCGGCAGACCCGGAGCAGCATGTGGA--------------------------CTCCTGGCGTCACCCAGCCCGGCCCAGGCCCAGAC  Δ26 x5 
GGCGGCAGACCCGGAGCAGCATGTGGACTCTCGGGCGCCGCGC---AGCCGGCCTCCTGGCGTCACCCAGCCCGGCCCAGGCCCAGAC  Δ3 x4 
GGCGGCAGACCCGGAGCAGCATGTGGACTCTCGGGC---------------GCCTCCTGGCGTCACCCAGCCCGGCCCAGGCCCAGAC  Δ15 x3 
GGCGGCAGACCCGGAGCAGCATGTGGACTCTCGG---------------------------GTCACCCAGCCCGGCCCAGGCCCAGAC  Δ27 x3 	
GATA4																												Mutations	in	14	of	2857	sequences	≈	0.5% 
GGGAGCTCGCAGGGACCATGTATCAGAGCTTGGCCATGGCCGCCAACCACGGGCCGCCCCCCGGTGCCTACGAGGCGGGCGGCCCCGG  WT 
GGGAGCTCGCAGGGACCATGTATCAGAGCTTGGCCATGGCCGCCAACCACGGG----CCCCCGGTGCCgTACGAGGCGGGCGGCCCCG  Δ3 (Δ4 +1) x1 
GGGAGCTCGCAGGGACCATGTATCAGAGCTTGGCCATGGCCGCCAA----------------------------------GGCCCCgG  Δ33 (Δ34 +1) x1 
GGGAGCTCGCAGGGACCATGTATCAGAGCTTGGCCATGGCCGCCA--CACG----GCCCCCCGGTGCCTACGAGGCGGGCGGCCCCGG  Δ6 x1 
GGGAGCTCGCAGGGACCATGTATCAGAGCTTGGCCATGGCCGCCAaccACCACGGGCCGCCCCCCGGTGCCTACGAGGCGGGCGGCCC  +3 x1 
GGGAGCTCGCAGGGACCATGTATCAGAGCTTGGCCATGGCCGCcaaCAACCACGGGCCGCCCCCCGGTGCCTACGAGGCGGGCGGCCC  +3 x1 	GATAD1																											Mutations	in	217	of	3832	sequences	≈	5.7% 
CCGTCCGCCATTCCCGTGTCTCTGCGCCCGCGGGGGCCGCCCGAGCCGGCCACCATGCCGCTGGGCCTGAAGCCCACCTGCAGCGTAT  WT 
CCGTCCGCCATTCCCGTGTCTCTGCGCCCGCGG-----------------------------GGGCCTGAAGCCCACCTGCAGCGTAT  Δ29 x14 
CCGTCCGCCATTCCCGTGTCTCTGCGCCCGCGGGGGCCGC-----------------CCGCTGGGCCTGAAGCCCACCTGCAGCGTAT  Δ17 x8 
CCGTCCGCCATTCCCGTGTCTCTGCGCCCGCG------------------------------GGGCCTGAAGCCCACCTGCAGCGTAT  Δ30 x6 
CCGTCCGCCATTCCCGTGTCTCTGCGCCCGCGGGGGCCGCCCGA---GGCCACCATGCCGCTGGGCCTGAAGCCCACCTGCAGCGTAT  Δ3 x5 
CCGTCCGCCATTCCCGTGTCTCTGCGCCCGCGGG-------------GGCCACCATGCCGCTGGGCCTGAAGCCCACCTGCAGCGTAT  Δ13 x5 	GLA																														Mutations	in	553	of	4338	sequences	≈	12.7% 
CTGAGGAACCCAGAACTACATCTGGGCTGCGCGCTTGCGCTTCGCTTCCTGGCCCTCGTTTCCTGGGACATCCCTGGGGCTAGAGCAC  WT 
CTGAGGAACCCAGAACTACATCTGGGCTGCGCGCTTG-----CGCTTCCTGGCCCTCGTTTCCTGGGACATCCCTGGGGCTAGAGCAC  Δ5 x41 
CTGAGGAACCCAGAACTACAT---------------------------CTGGCCCTCGTTTCCTGGGACATCCCTGGGGCTAGAGCAC  Δ27 x18 
CTGAGGAACCCAGAACTACATCTGGGCTGCG-----------CGCTTCCTGGCCCTCGTTTCCTGGGACATCCCTGGGGCTAGAGCAC  Δ11 x14 
CTGAGGAACCCAGAACTACATCTGGG----------------------CTGGCCCTCGTTTCCTGGGACATCCCTGGGGCTAGAGCAC  Δ22 x11 
CTGAGGAACCCAGAACTACATCTGGGCTGCGCGCTTGCG---CGCTTCCTGGCCCTCGTTTCCTGGGACATCCCTGGGGCTAGAGCAC  Δ3 x6 
 HOPX																													Mutations	in	75	of	2504	sequences	≈	3% 
CACCGCCGCCGCTTCTCCCTGCCCCGCAGCGCGCAGGGACCATGTCGGCGGAGACCGCGAGCGGCCCCACAGAGGACCAGGTGGAAAT  WT 
CACCGCCGCCGCTTCTCCCTGCCCCGCAGCGCGCAGG---------------GACCGCGAGCGGCCCCACAGAGGACCAGGTGGAAAT  Δ15 x5 
CACCGCCGCCGCTTCTCCCTGCCCCGCAGCGC---------------GCGGAGACCGCGAGCGGCCCCACAGAGGACCAGGTGGAAAT  Δ15 x3 
CACCGCCGCCGCTTCTCCCTGCCCCGCAGCGCGCAGGGACCATGT-------GACCGCGAGCGGCCCCACAGAGGACCAGGTGGAAAT  Δ7 x2 
CACCGCCGCCGCTTCTCCCTGCCCCGCAG--------------------------------------CACAGAGGACCAGGTGGAAAT  Δ38 x2 
CACCG-------------------------------------------------CCGCGAGCGGCCCCACAGAGGACCAGGTGGAAAT  Δ49 x2 	ILK																														Mutations	in	193	of	3547	sequences	≈	5.4% 
GGCTTCCCCAATCCAGGGGACTCGGCGCCGGGACGCTGCTATGGACGACATTTTCACTCAGTGCCGGGAGGGCAACGCAGTCGCCGTT  WT 
GGCTTCCCCAATCCAGGGGACTCGGCGCCGGGACGCTGCTATG---GACATTTTCACTCAGTGCCGGGAGGGCAACGCAGTCGCCGTT  Δ3 x28 
GGCTTCCCCAATCCAGGGGACTCGGCGCCGG---------------GACATTTTCACTCAGTGCCGGGAGGGCAACGCAGTCGCCGTT  Δ15 x7 
GGCTTCCCCAATCCAGGGGACTCGGCGCCGGGACGCTGCTAT----GACATTTTCACTCAGTGCCGGGAGGGCAACGCAGTCGCCGTT  Δ4 x6 
GGCTTCCCCAATCCAGGGGACTCGGCGCCGGGACGCTGCT---------ATTTTCACTCAGTGCCGGGAGGGCAACGCAGTCGCCGTT  Δ9 x6 
GGCTTCCCCAATCCAGGGGACTCGGCGCCGGGACGCTGCTATGgacGACGACATTTTCACTCAGTGCCGGGAGGGCAACGCAGTCGCC  +3 x4 	JAG1																													Mutations	in	125	of	2479	sequences	≈	5% 
CCCCACGGACGCGCGGCCGGTCCGGGCGCCCCCTAAGCCTCCTGCTCGCCCTGCTCTGTGCCCTGCGAGCCAAGGTAGGAGCCCTTCT  WT 
CCCCACGGACGCGCGGCCGGTCCGGGCGCCCCCTAA-----------GCCCTGCTCTGTGCCCTGCGAGCCAAGGTAGGAGCCCTTCT  Δ11 x8 
CCCCACGGACGCGCGGCCGGTCCGGGCGCCCCCTAAGCCTCctgCTGCTCGCCCTGCTCTGTGCCCTGCGAGCCAAGGTAGGAGCCCT  +3 x7 
CCCCACGGACGCGCGGCCGGTCCGGGCGCCCCCTAAGCCTCCTG------CTGCTCTGTGCCCTGCGAGCCAAGGTAGGAGCCCTTCT  Δ6 x3 
CCCCACGGACGCGCGGCCGGTCCGGGCGCCCCCTAAGCCT---------CCTGCTCTGTGCCCTGCGAGCCAAGGTAGGAGCCCTTCT  Δ9 x31 
CCCCACGGACGCGCGGCCGGTCCGGGCGCCCCCTAAGCCTCCTGCTC-----GCTCTGTGCCCTGCGAGCCAAGGTAGGAGCCCTTCT  Δ5 x2 	JPH2																													Mutations	in	41	of	2629	sequences	≈	1.6% 
ACGCTGGAGGACGGGGAGGTTGTCAGGGGCTATGATGAGATGAGTGGGGGCCGCTTCGACTTTGATGATGGAGGGGCGTACTGCGGGG  WT 
ACGCTGGAGGACGGGGAGGTTGTCAGGGGCTATGATGAGATGAGT-----CCGCTTCGACTTTGATGATGGAGGGGCGTACTGCGGGG  Δ5 x2 
ACGCTGGAGGACGGGGAGGTTGTC----------------------------------ACTTTGATGATGGAGGGGCGTACTGCGGGG  Δ34 x2 
ACGCTGGAGGACGGGGAGGTTGTCAGGGGCTATGATGAGATGAGTGGG---CGCTTCGACTTTGATGATGGAGGGGCGTACTGCGGGG  Δ3 x1 
ACGCTGGAGGACGGGGAGGTTGTCAGGGGCTATGATGAGATGAGTGG----CGCTTCGACTTTGATGATGGAGGGGCGTACTGCGGGG  Δ4 x1 
ACGCTGGAGGACGGGGAGGTTGTCAGGGGCTATGATGAGATGAGTG--------cTCGACTTTGATGATGGAGGGGCGTACTGCGGGG  Δ8 (Δ9 +1) x1 	JUP																														Mutations	in	34	of	4100	sequences	≈	0.8% 
TTCCTGCTTCCTGACTTCCTCCTTTGTGCCCCCAGTAGCCACGATGGAGGTGATGAACCTGATGGAGCAGCCTATCAAGGTGACTGAG  WT 
TTCCTGCTTCCTGACTTCCTCCT------------------------------TGAACCTGATGGAGCAGCCTATCAAGGTGACTGAG  Δ30 x3 
TTCCTGCTTCCTGACTTCCTCCTTTGTGCCCCCAGTAGCCAtC-----AGGTGATGAACCTGATGGAGCAGCCTATCAAGGTGACTGA  Δ4 (Δ5+1) x2 
TTCCTGCTTCCTGACTTCCTCCTTTGTGCCCCCAGTAGCCacgACGATGGAGGTGATGAACCTGATGGAGCAGCCTATCAAGGTGACT  +3 x2 
TTCCTGCTTCCTGACTTCCTCCTTTGTGCCCCCA-----------GGAGGTGATGAACCTGATGGAGCAGCCTATCAAGGTGACTGAG  Δ11 x2 
TTCCTGCTTCCTGACTTCCTCCTTTGTGCCCCCAGTAGCCACGATG--------GAACCTGATGGAGCAGCCTATCAAGGTGACTGAG  Δ8 x1 	LAMA4																												Mutations	in	57	of	1263	sequences	≈	4.5% 
GATGTCAGCGGAGAAATGGCTTTGAGCTCAGCCTGGCGCTCGGTTCTGCCTCTGTGGCTCCTCTGGAGCGCTGCCTGCTCCCGCGCCG  WT 
GATGTCAGCGGAGAAATGGCTTTGAGCTCAGC-------------CTGCCTCTGTGGCTCCTCTGGAGCGCTGCCTGCTCCCGCGCCG  Δ13 x4 
GATGTCAGCGGAGAAATGGCTTTGAGCTCAGCCTGGCGCTCGGT------TCTGTGGCTCCTCTGGAGCGCTGCCTGCTCCCGCGCCG  Δ6 x3 
GATGTCAGCGGAGAAATGGCTTTGAGCTCAGCCTGGCGC-----TCTGCCTCTGTGGCTCCTCTGGAGCGCTGCCTGCTCCCGCGCCG  Δ5 x2 
GATGTCAGCGGAGAAATGGCTTTGAGCTCAGCCTGGCG-------CTGCCTCTGTGGCTCCTCTGGAGCGCTGCCTGCTCCCGCGCCG  Δ7 x2 
CACG-------------------/ /-------------------CTGCCTCTGTGGCTCCTCTGGAGCGCTGCCTGCTCCCGCGCCG  Δ96 x1 	LAMP2																												Mutations	in	254	of	2092	sequences	≈	12.1% 
TCGCCGCCGTCGCCGCCTGCTCTGCGGGGTCATGGTGTGCTTCCGCCTCTTCCCGGTTCCGGGCTCAGGGCTCGTTCTGGTCTGCCTA  WT 
TCGCCGCCGTCGCCGCCTGCTCTGCGGGGTCATGGTGTG-------CTCTTCCCGGTTCCGGGCTCAGGGCTCGTTCTGGTCTGCCTA  Δ7 x26 
TCGCCGCCGTCGCCGCCTGCTCTGCGGGGTCATGGTGTG---------CTTCCCGGTTCCGGGCTCAGGGCTCGTTCTGGTCTGCCTA  Δ9 x18 
TCGCCGCCGTCGCCGCCTGCTCTGCGGGGTCATGGTGT------------------------GCTCAGGGCTCGTTCTGGTCTGCCTA  Δ24 x14 
TCGCCGCCGTCGCCGCCTGCTCTGCGGGGTCATGGTGT------GCCTCTTCCCGGTTCCGGGCTCAGGGCTCGTTCTGGTCTGCCTA  Δ6 x4 
TCGCCGCCGTCGCCGCCTGCTCTGCGGGGTCATGGTGTGCTT---------------------CTCAGGGCTCGTTCTGGTCTGCCTA  Δ21 x3 
 LMNA																													Mutations	in	183	of	1459	sequences	≈	12.5% 
CGCTGCCAACCTGCCGGCCATGGAGACCCCGTCCCAGCGGCGCGCCACCCGCAGCGGGGCGCAGGCCAGCTCCACTCCGCTGTCGCCC  WT 
CGCTGCCAACCTGCCGGCCATGGAGACCCCGTC--------------------------------CCAGCTCCACTCCGCTGTCGCCC  Δ32 x18 
CGCTGCCAACCTGCCGGCCATGGAGACCCCGTCCCAGC-------------------GGCGCAGGCCAGCTCCACTCCGCTGTCGCCC  Δ19 x10 
CGCTGCCAACCTGCCGGCCATGGAGACCCCGTCCCAGCGGCGcgcCGCCACCCGCAGCGGGGCGCAGGCCAGCTCCACTCCGCTGTCG  +3 x7 
CGCTGCCAACCTGCCGGCCATGGAGACCCCGTCC-----------------CAGCGGGGCGCAGGCCAGCTCCACTCCGCTGTCGCCC  Δ17 x6 
CGCTGCCAACCTGCCGGCCATGGAGACCCCGTCCCAGCGGCGcgccCGCCACCCGCAGCGGGGCGCAGGCCAGCTCCACTCCGCTGTC  +4 x5 	MLYCD																												Mutations	in	611	of	2282	sequences	≈	26.8% 
AGCGGCGGCGGCGCTCCCCCTCGGCAGCTGTTGTGGGGCACCATGCGAGGCTTCGGGCCAGGCTTGACGGCCAGGCGTCTCCTCCCGC  WT 
AGCGGCGGCGGCGCTCCCCCTCGGCAGCTGTTGTGG------------GGCTTCGGGCCAGGCTTGACGGCCAGGCGTCTCCTCCCGC  Δ12 x50 
AGCGGCGGCGGCGCTCCCCCTCGGCAGCTGTTGT------------GAGGCTTCGGGCCAGGCTTGACGGCCAGGCGTCTCCTCCCGC  Δ12 x31 
AGCGGCGGCGGCGCTCCCCCTCGGCAGCTGTTGTG-------------------GGGCCAGGCTTGACGGCCAGGCGTCTCCTCCCGC  Δ19 x19 
AGCGGCGGCGGCGCTCCCCCTCGGCAGCTGT------------TGCGAGGCTTCGGGCCAGGCTTGACGGCCAGGCGTCTCCTCCCGC  Δ12 x14 
AGCGGCGGCGGCGCTCCCCCTCGGCAGCTGTTGT--------------------GGGCCAGGCTTGACGGCCAGGCGTCTCCTCCCGC  Δ20 x13 	MYBPC3																											Mutations	in	13	of	1895	sequences	≈	0.7% 
TGGGTGACCTGTGCCTGCTTCGTGCCTGGTGTGACGTCTCTCAGGATGCCTGAGCCGGGGAAGAAGCCAGGTAGCTTTAGGACTGGGG  WT 
TGGGTGACCTGTGCCTGCTTCGTGCCTGGTG---------------TGCCTGAGCCGGGGAAGAAGCCAGGTAGCTTTAGGACTGGGG  Δ15 x3 
TGGGTGACCTGTGCCTGCTTCGTGCCTGGTGT------------GATGCCTGAGCCGGGGAAGAAGCCAGGTAGCTTTAGGACTGGGG  Δ12 x2 
TGGGTGACCTGTGCCTGCTTCGTGCCTGGTGTGACGTCTCTCaggAGGATGCCTGAGCCGGGGAAGAAGCCAGGTAGCTTTAGGACTG  +3 x1 
TGGGTGACCTGTGCCTGCTTCGTGCCTGGTGTGACGTC--------TGCCTGAGCCGGGGAAGAAGCCAGGTAGCTTTAGGACTGGGG  Δ8 x1 
TGGGTGACCTGTGCCTGCTTCGTGCCTGGTGTGACGT---TCAGGAT-CCTGAGCCGGGGAAGAAGCCAGGTAGCTTTAGGACTGGGG  Δ4 x1 	MYH6																													Mutations	in	172	of	1845	sequences	≈	9.3% 
GGAGTAACATAGCCCTCCTGTCTCTGACCCAGGGGAAGCACCAAGATGACCGATGCCCAGATGGCTGACTTTGGGGCAGCGGCCCAGT  WT 
GGAGTAACATAGCCCTCCTGTCTCTGACCCAGGGGAAGC---------ACCGATGCCCAGATGGCTGACTTTGGGGCAGCGGCCCAGT  Δ9 x20 
AGCC---------------------------------------/ /---------------------------------------CTG  Δ262 x9 
GGAGTAACATAGCCCTCCTGTCTCTGACCCA-GGGAAGC---------ACCGATGCCCAGATGGCTGACTTTGGGGCAGCGGCCCAGT  Δ10 x5 
GGAGTAACATAGCCCTCCTGTCTC----------------------TGACCGATGCCCAGATGGCTGACTTTGGGGCAGCGGCCCAGT  Δ22 x5 
GCCA--------------------/ /---------------------ACCGATGCCCAGATGGCTGACTTTGGGGCAGCGGCCCAGT  Δ255 x4 	MYH7																													Mutations	in	176	of	2894	sequences	≈	6.1% 
CCAGGCACAGCCATGGGAGATTCGGAGATGGCAGTCTTTGGGGCTGCCGCCCCCTACCTGCGCAAGTCAGAGAAGGAGCGGCTAGAAG  WT 
CCAGGCACAGCCATGGGAGATTCGGAGATGGCAGTCTTTGGGGCTGC-------------CGCAAGTCAGAGAAGGAGCGGCTAGAAG  Δ13 x49 
CCAGGCACAGCCATGGGAGATTCGGAGATGGCAGTCTTT-GGGCTGC-------------CGCAAGTCAGAGAAGGAGCGGCTAGAAG  Δ14 x10 
CCAGGCACAGCCATGGGAGATTCGGAGATGGCAGTCTTTGGGGCTG----------CCTGCGCAAGTCAGAGAAGGAGCGGCTAGAAG  Δ10 x5 
CCAGGCACAGCCATGGGAGATTCGGAGATGGCAGTCTT-------------CCCTACCTGCGCAAGTCAGAGAAGGAGCGGCTAGAAG  Δ13 x4 
CCAGGCACAGCCATGGGAGATTCGGAGATGGCAGTCTTTGGGGCTG-----CgCTA-CTGCGCAAGTCAGAGAAGGAGCGGCTAGAAG  Δ6 (Δ7 +1) x3 	MYH7																													Mutations	in	1143	of	2276	sequences	≈	50.2% 
CAGCCATGGGAGATTCGGAGATGGCAGTCTTTGGGGCTGCCGCCCCCTACCTGCGCAAGTCAGAGAAGGAGCGGCTAGAAGCGCAGAC  WT 
CAGCCATGGGAGATTCGGAGATGGCAGTCTTTGGGGCTGC-------------CGCAAGTCAGAGAAGGAGCGGCTAGAAGCGCAGAC  Δ13 x488 
CAGCCATGGGAGATTCGGAGATGGCAGTCTTT-GGGCTGC-------------CGCAAGTCAGAGAAGGAGCGGCTAGAAGCGCAGAC  Δ14 x137 
CAGCCATGGGAGATTCGGAGATGGCAGTCTT-------------CCCTACCTGCGCAAGTCAGAGAAGGAGCGGCTAGAAGCGCAGAC  Δ13 x115 
CAGCCATGGGAGATTCGGAGATGGCAGTCTTTGGGGCTG----------CCTGCGCAAGTCAGAGAAGGAGCGGCTAGAAGCGCAGAC  Δ10 x15 
CAGCCATGGGAGATTCGGAGATGGCAGTCTTTGGGG--------------CTGCGCAAGTCAGAGAAGGAGCGGCTAGAAGCGCAGAC  Δ14 x10 	MYL2																													Mutations	in	20	of	3949	sequences	≈	0.5% 
AATTCTTCTCGGGAGGCAGTGCTGGGTCCTTTCCACCATGGTGAGTACAAGGGCTCCAGGAGGTGATGATGCCGGGTGGGCGAGGAGA  WT 
AATTCTTCTCGGGAGGCAGTGCTGGGTCCTTTCCACCA---TGtGTACAAGGGCTCCAGGAGGTGATGATGCCGGGTGGGCGAGGAGA  Δ3 (Δ4 +1) x2 
AATTCTTCTCGGGAGGCAGTGCTGGGTCCTTTCCACCATGGTGAGT---AaGGCTCCAGGAGGTGATGATGCCGGGTGGGCGAGGAGA  Δ3 (Δ4 +1) x1 
AATTCTTCTCGGGAGGCAGTGCTGGGTCCTTTCCACCATGGTGAGTgaaagacACAAGGGCTCCAGGAGGTGATGATGCCGGGTGGGC  +7 x1 
AATTCTTCTCGGGAGGCAGTGCTGGGTCCTTTCCACCATGGTGAGTggaaaggaccACAAGGGCTCCAGGAGGTGATGATGCCGGGTG  +10 x1 
AATTCTTCTCGGGAGGCAGTGCTGGGTCCTTTCCACCATGGTGagtAGTACAAGGGCTCCAGGAGGTGATGATGCCGGGTGGGCGAGG  +3 x1 	MYL3																													Mutations	in	171	of	2199	sequences	≈	7.8% 
TTCTCTCCACATCCCTCTCTGTACTTACAGCCCCCAATGGCCCCCAAAAAGCCAGAGCCCAAGAAGGATGATGCCAAGGCAGCCCCCA  WT 
TTCTCTCCACATCCCTCTCTGTACTTACAGCCCCCAATG-----------GCCAGAGCCCAAGAAGGATGATGCCAAGGCAGCCCCCA  Δ11 x18 
TTCTCTCCACATCCCTCTCTGTACTTACAG-CCCCAATG-----------GCCAGAGCCCAAGAAGGATGATGCCAAGGCAGCCCCCA  Δ12 x5 
TTCTCTCCACATCCCTCTCTGTACTTACAGCCCCCAATG-----------GCCAGAGCCCAAGAAGGATGATGCCAAGGCAG-CCCCA  Δ12 x4 
TTCTCTCCACATCCCTCTCTGTACTTACA----------GCCCCCAAAAAGCCAGAGCCCAAGAAGGATGATGCCAAGGCAGCCCCCA  Δ10 x4 
TTCTCTCCACATCCCTCTCTGTACTTACAGCCCCCAATGGCCC---AAAAGCCAGAGCCCAAGAAGGATGATGCCAAGGCAGCCCCCA  Δ3 x2 	MYLK2																												Mutations	in	254	of	4248	sequences	≈	6% 
ACAAGCAGCAGCACACGCCTCCCTACCTCATGGCGACAGAAAATGGAGCAGTTGAGCTGGGAATTCAGAACCCATCAACAGGTGCCAA  WT 
ACAAGCAGCAGCACACGCCTCCCTACCTCATGGCGAC---------AGCAGTTGAGCTGGGAATTCAGAACCCATCAACAGGTGCCAA  Δ9 x22 
ACAAGCAGCAGCACACGCCTCCCTACCTCATGGCGA------------CAGTTGAGCTGGGAATTCAGAACCCATCAACAGGTGCCAA  Δ12 x12 
ACAAGCAGCAGCACACGCCTCCCTACCTCATGGCGACA-------GAGCAGTTGAGCTGGGAATTCAGAACCCATCAACAGGTGCCAA  Δ7 x10 
ACAAGCAGCAGCACACGCCTCCCTACCTCATGGCGACAGAAAAtggTGGAGCAGTTGAGCTGGGAATTCAGAACCCATCAACAGGTGC  +3 x5 
ACAAGCAGCAGCACACGCCTCCCTACCTCATGGCGACAGAA--------AGTTGAGCTGGGAATTCAGAACCCATCAACAGGTGCCAA  Δ8 x5 
ACAAGCAGCAGCACACGCCTCCCTACCTCATGGCGACA---------------GAGCTGGGAATTCAGAACCCATCAACAGGTGCCAA  Δ15 x5 	MYOM1																												Mutations	in	35	of	4149	sequences	≈	0.8% 
TTCCTTCAGGTGGCCCGGTTCCTTCAAGGGGCACAGGATGTCTTTGCCTTTTTATCAGAGGTGCCACCAGCACTATGATCTCAGCTAC  WT 
TTCCTTCAGGTGGCCCGGTTCCTTCAAGaGGCACAGGATGTCTTTG-----TTATCAGAGGTGCCACCAGCACTATGATCTCAGCTAC  Δ5 (Δ6 +1) x2 
TTCCTTCAGGTGGCCCGGTTCCTTCAAGaGGCACAGGATGTCTttgTTGCCTTTTTATCAGAGGTGCCACCAGCACTATGATCTCAGC  +3 (Δ1 +4) x2 
TTCCTTCAGGTGGCCCGGTTCCTTCAAGGGGCACAGGATGTCTTTGC---TTTA------GTG----CAcCACTATGATCTCAGCTAC  Δ13 (Δ14 +1) x1 
TTCCTTCAGGTGGCCCGGTTCCTTCAAGGGGCACAGGATGTCTTTGC-----TATCAGAGGTGCCACCAGCACTATGATCTCAGCTAC  Δ5 x1 
TTCCTTCAGGTGGCCCGGTTCCTTCAAGGGGCACAGGATGTCTttgTTGCCTTTTTATCAGAGGTGCCACCAGCACTATGATCTCAGC  +3 x1 
 MYOZ2																												Mutations	in	67	of	4653	sequences	≈	1.4% 
AAAAAAACCATGCTATCACATAATACTATGATGAAGCAGAGAAAACAGCAAGCAACAGCCATCATGAAGGAAGTCCATGGAAATGGTA  WT 
AAAAAAACCATGCTATCACATAATACTATGATGAAGCAG-----------AGCAACAGCCATCATGAAGGAAGTCCATGGAAATGGTA  Δ11 x10 
AAAAAAACCATGCTATCACATAATACTATGATGAAGCAG-------AGCAAGCAACAGCCATCATGAAGGAAGTCCATGGAAATGGTA  Δ7 x4 
AAAAAAACCATGCTATCACATAATACTATGATG----------------AAGCAACAGCCATCATGAAGGAAGTCCATGGAAATGGTA  Δ16 x4 
AAAAAAACCATGCTATCACATAATACTATGATGAAGCAGAGA----AGCAAGCAACAGCCATCATGAAGGAAGTCCATGGAAATGGTA  Δ4 x2 
AAAAAAACCATGCTATCACATAATACTATGATGAAGCAGAGA-------cAGCAACAGCCATCATGAAGGAAGTCCATGGAAATGGTA  Δ7 (Δ8+1) x2 	MYPN																													Mutations	in	345	of	1389	sequences	≈	24.8% 
AAACTTTTTGTTATTATTATTTTGTGACAGCATGCAAGACGACAGCATAGAAGCTTCTACTTCCATATCTCAGCTTCTAAGAGAGAGC  WT 
AAACTTTTTGTTATTATTATTTTGTGACAGCATGCA-----------------------/ /-----------------------AGA  Δ210 x12 
AAACTTTTTGTTATTATTATTTTGTGACAGCAT-----------GCATAGAAGCTTCTACTTCCATATCTCAGCTTCTAAGAGAGAGC  Δ11 x11 
AAACTTTTTGTTATTATTATTTTGTGACAGCATGCAA---GACAGCATAGAAGCTTCTACTTCCATATCTCAGCTTCTAAGAGAGAGC  Δ3 x9 
AAACTTTTTGTTATTATTATTTTGTGACAGCATGCA----GACAGCATAGAAGCTTCTACTTCCATATCTCAGCTTCTAAGAGAGAGC  Δ4 x5 
AAACTTTTTGTTATTATTATTTTGTGACAGCATGCAAGACGAC--------AGCTTCTACTTCCATATCTCAGCTTCTAAGAGAGAGC  Δ8 x4 	NEBL																													Mutations	in	44	of	3474	sequences	≈	1.3% 
AATATTTTAAAGGGTAAAAATGAGGGTCCCTGTATTTGAGGATATAAAAGATGAAACTGAAGAAGAAAAGATAGGGGAAGAAGAAAAT  WT 
AATATTTTAAAGGGTAAAAATGAGGGTCCCTGTATTTGAGGAtatTATAAAAGATGAAACTGAAGAAGAAAAGATAGGGGAAGAAGAA  +3 x2 
AATATTTTAAAGGGTAAAAATGAGGGTCCCTGTATTTGAGG-----AAAGATGAAACTGAAGAAGAAAAGATAGGGGAAGAAGAAAAT  Δ5 x2 
AATATTTTAAAGGGTAAAAATGAGGGTCCCTGT---------TATAAAAGATGAAACTGAAGAAGAAAAGATAGGGGAAGAAGAAAAT  Δ9 x2 
AATATTTTAAAGGGTAAAAATGAGGGTCCCTGT----------------------ACTGAAGAAGAAAAGATAGGGGAAGAAGAAAAT  Δ22 x2 
AATATTTTAAAGGGTAAAAATGAGGGTCCC---------------------TGAAACTGAAGAAGAAAAGATAGGGGAAGAAGAAAAT  Δ21 x2 
 NEXN																													Mutations	in	179	of	1508	sequences	≈	11.9% 
ATAATCAGCCCAAGACCACATAGAGCAAACATGAATGATATTTCCCAAAAGGCTGAGGTAAGTCTCAAAAGTAAAAATAAAAATAAAA  WT 
ATAATCAGCCCAAGACCACATAGAGCAAA----------------CAAAAGGCTGAGGTAAGTCTCAAAAGTAAAAATAAAAATAAAA  Δ16 x9 
ATAATCAGCCCAAGACCACATAGAGCAAACATGAA------------------TGAGGTAAGTCTCAAAAGTAAAAATAAAAATAAAA  Δ18 x8 
ATAATCAGCCCAAGACCACATAGAGCAAACA----------------------TGAGGTAAGTCTCAAAAGTAAAAATAAAAATAAAA  Δ22 x4 
ATAATCAGCCCAAGACCACATAGAGCAAACATGAATGATATTTCC-----GGCTGAGGTAAGTCTCAAAAGTAAAAATAAAAATAAAA  Δ5 x3 
ATAATCAGCCCAAGACCACATAGAGCAAACATGAATGATATT---CAAAAGGCTGAGGTAAGTCTCAAAAGTAAAAATAAAAATAAAA  Δ3 x3 	NKX2-5																												Mutations	in	132	of	1404	sequences	≈	9.4% 
CTGCCGCCCACCTGGCGCTGTGAGACTGGCGCTGCCACCATGTTCCCCAGCCCTGCTCTCACGCCCACGCCCTTCTCAGTCAAAGACA  WT 
CTGCCGCCCACCTGGCGCTGTGAGACTGGCGCTG------------CCAGCCCTGCTCTCACGCCCACGCCCTTCTCAGTCAAAGACA  Δ12 x12 
CTGCCGCCCACCTGGCGCTGTGAGACTGGCGCTGCCA---------CCAGCCCTGCTCTCACGCCCACGCCCTTCTCAGTCAAAGACA  Δ9 x7 
CTGCCGCCCACCTGGCGCTGTGAGACTGGCGCTGCCACCATGTT-----------CTCTCACGCCCACGCCCTTCTCAGTCAAAGACA  Δ11 x3 
CTGCCGCCCACCTGGCGCTGTGAGACTGGCGCTGCCACCATG----CCAGCCCTGCTCTCACGCCCACGCCCTTCTCAGTCAAAGACA  Δ4 x3 
CTGCCGCCCACCTGGCGCTGTGAGACTGGCGCTGCCACCATG---CCCAGCCCTGCTCTCACGCCCACGCCCTTCTCAGTCAAAGACA  Δ3 x2 
 PDLIM3																											Mutations	in	29	of	2445	sequences	≈	1.2% 
GGCTGCCCTGCGCGGGGACACTCAGAGCCCGGTGGGCGGGAGGAAGGCGGCATGCCCCAGACGGTGATCCTCCCGGGCCCTGCGCCCT  WT 
GGAC----------------------------------/ /-----------------------------------GCCCTGCGCCCT  Δ93 x3 
GGCTGCCC--------------------------------------------------------TGATCCTCCCGGGCCCTGCGCCCT  Δ56 x3 
GGCTGCCCTGCGCGGGGACACTCAGAGCCCGGTGGGC------AAGGCGGCATGCCCCAGACGGTGATCCTCCCGGGCCCTGCGCCCT  Δ6 x2 
GGCTGCCCTGCGCG------------------------------------------------GGTGATCCTCCCGGGCCCTGCGCCCT  Δ48 x2 
ACGC---------------------------/ /---------------------------CGGTGATCCTCCCGGGCCCTGCGCCCT  Δ76 x1 	PKP2																													Mutations	in	132	of	2979	sequences	≈	4.4% 
CCAGAGGCAGGCGAGCAGCTCGGTCGCCCCCACCGGCCCCATGGCAGCCCCCGGCGCCCCAGCTGAGTACGGCTACATCCGGACCGTC  WT 
CCAGAGGCAGGCGAGCAGCTCGGTCGCCCCCACCG-----------GCCCCCGGCGCCCCAGCTGAGTACGGCTACATCCGGACCGTC  Δ11 x12 
CCAGAGGCAGGCGAGCAGCTCGGTCGCCCCCA------------------CCGGCGCCCCAGCTGAGTACGGCTACATCCGGACCGTC  Δ18 x10 
CCAGAGGCAGGCGAGCAGCTCGGTCGCCCCCACCG--------------------GCCCCAGCTGAGTACGGCTACATCCGGACCGTC  Δ20 x8 
CCAGAGGCAGGCGAGCAGCTCGGTCGCCCCCACCGG------------CCCCGGCGCCCCAGCTGAGTACGGCTACATCCGGACCGTC  Δ12 x7 
CCAGAGGCAGGCGAGCAGCTCGGTCGCC-------------------CCCCCGGCGCCCCAGCTGAGTACGGCTACATCCGGACCGTC  Δ19 x5 
 PLN																														Mutations	in	8	of	1097	sequences	≈	0.7% 
GACCACTTAAAACTTCAGACTTCCTGTCCTGCTGGTATCATGGAGAAAGTCCAATACCTCACTCGCTCAGCTATAAGAAGAGCCTCAA  WT 
GACCACTTAAAACTTCAGACTTCCTGTCCTGCTGGTATCATGGctggtatcatAG-gAGTCCAATACCTCACTCGCTCAGCTATAAGA  +9 (Δ2 +11) x1 
GACCACTTAAAACTTCAGACTTCCTGTCCTGCTGGTATCATG----AAaTCC-ATACCTCACTCGCTCAGCTATAAGAAGAGCCTCAA  Δ5 (Δ6 +1) x1 
GACCACTTAAAACTTCAGACTTCCTGTCCTGCTGGTATCATG-----AGTCCAATACCTCACTCGCTCAGCTATAAGAAGAGCCTCAA  Δ5 x1 
GACCACTTAAAACTTCAGACTTCCTGTCCTGCTGGTATCAT---GAAAGTCCAATACCTCACTCGCTCAGCTATAAGAAGAGCCTCAA  Δ3 x1 
GACCACTTAAAACTTCAGACTTCCTGTCCTGCT-GTA-CATG--------------CaTCACTCGCTCAGCTATAAGAAGAGCCTCAA  Δ16 (Δ17 +1) x1 	PRKAG2																											Mutations	in	117	of	2433	sequences	≈	4.8% 
CCCGAGGAGTTTCGCAGAATCAACTTCTGGTTAGAGTTATGGGAAGCGCGGTTATGGACACCAAGAAGAAAAAAGATGTTTCCAGCCC  WT 
CCCGAGGAGTTTCGCAGAATCAACTTCTGGTTAGA---------------GTTATGGACACCAAGAAGAAAAAAGATGTTTCCAGCCC  Δ15 x22 
CCCGAGGAGTTTCGCAGAATCAACTTCTGGTTAGAGTTAT---------------------/ /---------------------GGc  Δ178 x20 
CCCGAGGAGTTTCGCAGAATCAACTTCTGGTTAGA---------------GTTATGGACACCAAGAAG-AAAAAGATGTTTCCAGCCC  Δ16 x4 
CCCGAGGAGTTTCGCAGAATCAACTTCTGGTTAGA---------------GTTATGGACACCAAGAAGAAAAAAGATGTTTCCAG-CC  Δ16 x3 
CCCGAGGAGTTTCGCAGAATCAACTTCTGGTTAGAGTTATGGgaaGAAGCGCGGTTATGGACACCAAGAAG-AAAAAGATGTTTCCAG  +2 (Δ1 +3) x2 
 PSEN1																												Mutations	in	88	of	3807	sequences	≈	2.3% 
TGTTTTCTGTGAAACAGTATTTCTATACAGTTGCTCCAATGACAGAGTTACCTGCACCGTTGTCCTACTTCCAGAATGCACAGATGTC  WT 
TGTTTTCTGTGAAACAGTATTTCTATACAGTTGCTCCAATgacaGACAGAGTTACCTGCACCGTTGTCCTACTTCCAGAATGCACAGA  +4 x5 
TGTTTTCTGTGAAACAGTATTTCTATACAGTTGCTCCAATG--------ACCTGCACCGTTGTCCTACTTCCAGAATGCACAGATGTC  Δ8 x4 
TGTTTTCTGTGAAACAGTATTTCTATACAGTTGCTCCAATG--------------ACCGTTGTCCTACTTCCAGAATGCACAGATGTC  Δ14 x4 
TGTTTTCTGTGAAACAGTATTTCTATACAGTTGCTCCAAT------GTTACCTGCACCGTTGTCCTACTTCCAGAATGCACAGATGTC  Δ6 x4 	PSEN2																												Mutations	in	344	of	2888	sequences	≈	11.9% 
AAGGTCCTTGTGCTCCTTTTTCCAGGTGCTTCCAGAGGCAGGGCTATGCTCACATTCATGGCCTCTGACAGCGAGGAAGAAGTGTGTG  WT 
AAGGTCCTTGTGCTCCTTTTTCCAGGTGCTTCCAGAGGCAGG----TGCTCACATTCATGGCCTCTGACAGCGAGGAAGAAGTGTGTG  Δ4 x12 
AAGGTCCTTGTGCTCCTTTTTCCAGGTGCTTCCAGAG----------GCTCACATTCATGGCCTCTGACAGCGAGGAAGAAGTGTGTG  Δ10 x11 
AAGGTCCTTGTGCTCCTTTTTCCAGGTGCTTCCAGAGGCA-------GCTCACATTCATGGCCTCTGACAGCGAGGAAGAAGTGTGTG  Δ7 x9 
AAGGTCCTTGTGCTCCTTTTTCCAGGTGCTTCCAGAGGCAG------GCTCACATTCATGGCCTCTGACAGCGAGGAAGAAGTGTGTG  Δ6 x8 
AAGGTCCTTGTGCTCCTTTTTCCAGGTGCTTCCAGA-----------------------/ /-----------------------GGC  Δ172 x7 
 PTPN11																											Mutations	in	58	of	1498	sequences	≈	3.9%	
CCTGAGCAAGGAGCGGGTCCGTCGCGGAGCCGGAGGGCGGGAGGAACATGACATCGCGGAGGTGAGGAGCCCCGAGGGGCCCGGCGCG  WT 
CCTGAGCAAGGAGCGGGTCCGTCGCGGAGCCGGAGGGCGGGAGgaacGAACATGACATCGCGGAGGTGAGGAGCCCCGAGGGGCCCGG  +4 x2 
CCTGAGCAAGGAGCGGGTCCGTCGCGGAGCCGGAGGGCGGGA-------GACATCGCGGAGGTGAGGAGCCCCGAGGGGCCCGGCGCG  Δ7 x2 
CCTGAGCAAGGAGCGGGTCCGTCGCGGAGCCGGAGGGCG---GGAACATGACATCGCGGAGGTGAGGAGCCCCGAGGGGCCCGGCGCG  Δ3 x2 
CCTGAGCAAGGAGCGGGTCCGTCGCGGAGC---------GGAGGAACATGACATCGCGGAGGTGAGGAGCCCCGAGGGGCCCGGCGCG  Δ9 x2 
CCTGAGCAAGGAGCGGGTCCGTCGCGGAGCCGGAGGGCGGGAGGA-----------------TGAGGAGCCCCGAGGGGCCCGGCGCG  Δ17 x1 	RAF1																													Mutations	in	70	of	1725	sequences	≈	4.1% 
TTACCAGGTTTAAGAATTGTTTAAGCTGCATCAATGGAGCACATACAGGGAGCTTGGAAGACGATCAGCAATGGTTTTGGATTCAAAG  WT 
TTACCAGGTTTAAGAATTGTTTAAGCTGCATCAAT-------------GGAGCTTGGAAGACGATCAGCAATGGTTTTGGATTCAAAG  Δ13 x6 
TTACCAGGTTTAAGAATTGTTTAAGCTGCATCAAT------------GGGAGCTTGGAAGACGATCAGCAATGGTTTTGGATTCAAAG  Δ12 x2 
TTACCAGGTTTAAGAATTGTTTAAGCTGCATCA-------------AGGGAGCTTGGAAGACGATCAGCAATGGTTTTGGATTCAAAG  Δ13 x2 
TTACCAGGTTTAAGAATTGTTTAAGCTGCAT--------------CAGGGAGCTTGGAAGACGATCAGCAATGGTTTTGGATTCAAAG  Δ14 x2 
TTACCAGGTTTAAGAATTGTTTAAGCTGCATCAATGGAGCACAT--------------AGACGATCAGCAATGGtTTTTGGATTCAAA  Δ13 (Δ14 +1) x1 	RBM20																												Mutations	in	152	of	4228	sequences	≈	3.6% 
CCTTGAGCTCTCTCGCCGCGATCCCGGGCGGGTCTCGCCCCGCATGGTGCTGGCAGCAGCCATGAGCCAGGACGCGGACCCCAGCGGT  WT 
CCTTGAGCTCTCTCGCCGCGATCCCGGGCGGGTCTC------------GCTGGCAGCAGCCATGAGCCAGGACGCGGACCCCAGCGGT  Δ12 x5 
CCTTGAGCTCTCTCGCCGCGATCCCGG---------------------GCTGGCAGCAGCCATGAGCCAGGACGCGGACCCCAGCGGT  Δ21 x5 
CCTTGAGCTCTCTCGCCGCGATCCCGGGCGGGTCTCGCCCCGCA------TGGCAGCAGCCATGAGCCAGGACGCGGACCCCAGCGGT  Δ6 x4 
CCTTGAGCTCTCTCGCCGCGATCCCGGGCGGGTCTC----------------GCAGCAGCCATGAGCCAGGACGCGGACCCCAGCGGT  Δ16 x4 
CCTTGAGCTCTCTCGCCGCGATCCCG-------------------------GGCAGCAGCCATGAGCCAGGACGCGGACCCCAGCGGT  Δ25 x4 	RYR2																													Mutations	in	11	of	1322	sequences	≈	0.8% 
GGCGAGGAGGCGCGGAACCATGGCCGATGGGGGCGAGGGCGAAGACGAGATCCAGTTCCTGCGAACTGTAAGCGCCGTGCGTCGCGTG  WT 
GGCGAGGAGGCGCGGAACCATGGCCGATGGGGGCGAGGGCGAAgacGACGAGATCCAGTTCCTGCGAACTGTAAGCGCCGTGCGTCGC  +3 x3 
GGCGAGGAGGCGCGGAACCATGGCCGATGGGGGCGAGGGCGAAGACGA----CAGT-----gGAACTGTAAGCGCCGTGCGTCGCGTG  Δ9 (Δ10 +1) x1 
GGCGAGGAGGCGCGGAACCATGGCCGATGGGGGCGAGGGCGAActgtaagcgatgGcCGAtgggggcGATCCAGTTCCTGCGAACTGT  +19 (Δ1 +20) x1 
GGCGAGGAGGCGCGGAACCATGGCCGATGGGGGCGAGGGCGA----GcGATCCAGTTCCTGCGAACTGTAAGCGCCGTGCGTCGCGTG  Δ4 (Δ5 +1) x1 
GGCGAGGAGGCGCGGAACCATGGCCGATGGGGGCGAGGGCGA-----AGATCCAGTTCCTGCGAACTGTAAGCGCCGTGCGTCGCGTG  Δ5 x1 
 SCN5A																												Mutations	in	87	of	4481	sequences	≈	1.9% 
CCTGTGCCCAGAAGCAGGATGAGAAGATGGCAAACTTCCTATTACCTCGGGGCACCAGCAGCTTCCGCAGGTTCACACGGGAGTCCCT  WT 
CCTGTGCCCAGAAGCAGGATGAGAAGATGGCAAACTT-------CCTCGGGGCACCAGCAGCTTCCGCAGGTTCACACGGGAGTCCCT  Δ7 x5 
CCTGTGCCCAGAAGCAGGATGAGAAGATGGCAAACT----------TCGGGGCACCAGCAGCTTCCGCAGGTTCACACGGGAGTCCCT  Δ10 x3 
CCTGTGCCCAGAAGCAGGATGAGAAGATGGCA-----CC----AgCTCGGGGCACCAGCAGCTTCCGCAGGTTCACACGGGAGTCCCT  Δ9 (Δ10+1) x3 
CCTGTGCCCAGAAGCAGGATGAGAAGATGGCAAACTTCCTATtacTACCTCGGGGCACCAGCAGCTTCCGCAGGTTCACACGGGAGTC  +3 x2 
CCTGTGCCCAGAAGCAGGATGAGAAGATGGCAAACTTC----------------CCAGCAGCTTCCGCAGGTTCACACGGGAGTCCCT  Δ16 x2 	SCO2																													Mutations	in	84	of	3459	sequences	≈	2.4% 
GGCTCCTGACGCCTGTGCTTGTTTCCAGGAGCATCAGATCCATGCTGCTGCTGACTCGGAGCCCCACAGCTTGGCACAGGCTCTCTCA  WT 
GGCTCCTGACGCCTGTGCTTGTTTCCAGGAGCATCAGATCCA---TGCTGCTGACTCGGAGCCCCACAGCTTGGCACAGGCTCTCTCA  Δ3 x15 
GGCTCCTGACGCCTGTGCTTGTTTCCAGG---ATCA-------------------TCGGAGCCCCACAGCTTGGCACAGGCTCTCTCA  Δ22 x3 
GGCTCCTGACGCCTGTGCTTGTTTCCAGGAGCATCAGATCCtggtgctgactcggagATcaGaTGCTGCTGACTCGGAGCCCCACAGC  +18 (Δ1 +19) x2 
GGCTCCTGACGCCTGTGCTTGTTTCCAGGAGCATC-------TGCTGCTGCTGACTCGGAGCCCCACAGCTTGGCACAGGCTCTCTCA  Δ7 x2 
GGCTCCTGACGCCTGTGCTTGTTTCCAGGAGCATC------------------------AGCCCCACAGCTTGGCACAGGCTCTCTCA  Δ24 x2 	SDHA																													Mutations	in	66	of	1815	sequences	≈	3.6% 
AACAGCAGACATGTCGGGGGTCCGGGGCCTGTCGCGGCTGCTGAGCGCTCGGCGCCTGGCGCTGGCCAAGGCGGTGAGTCCGTGCCGC  WT 
AACAGCAGACATGTCGGGGGTCCGGGGCCTGTCGCGGCTGCTGAGCG--------CTGGCGCTGGCCAAGGCGGTGAGTCCGTGCCGC  Δ8 x2 
AACAGCAGACATGTCGGGGGTCCGGGGCCTGTCGCGGCT-------GCTCGGCGCCTGGCGCTGGCCAAGGCGGTGAGTCCGTGCCGC  Δ7 x2 
AACAGCAGACATGTCGGGGGTCCGGGGCCTGTCGCGGCTGCTGAGCGCT---CGCCTGGCGCTGGCCAAGGCGGTGAGTCCGTGCCGC  Δ3 x1 
AACAGCAGACATGTCGGGGGTCCGGGGCCTGTCGCGGCTGCTGAGCGCT---------GCGCTGGCCAAGGCGGTGAGTCCGTGCCGC  Δ9 x1 
AACAGCAGACATGTCGGGGGTCCGGGGCCTGTCGCGGCTGCTGAGC-CT---CGCCTGGCGCTGGCCAAGGCGGTGAGTCCGTGCCGC  Δ4 x1 
 SGCD																													Mutations	in	7	of	2203	sequences	≈	0.3% 
AGACATTACTGCCGGGAGTGTTGAGTGAAGGGACCAGGTGGAGATGGTGAGTAATTCCCGGGAGCGAAGCTTGTTCAAGGCCCTGCTC  WT 
AGACATTACTGCCGGGAGTGTTGAGTGAAGGGACCAGGTGGAgatGATGGTGAGTAATTCCCGGGAGCGAAGCTTGTTCAAGGCCCTG  +3 x2 
AGACATTACTGCCGGGAGTGTTGAGTGAAGGGACCAGGT---GAT-GTGAGTAATTCCCGGGAGCGAAGCTTGTTCAAGGCCCTGCTC  Δ4 x1 
AGACATTACTGCCGGGAGTGTTGAGTGAAGGGACCAG-----GATGGTGAGTAATTCCCGGGAGCGAAGCTTGTTCAAGGCCCTGCTC  Δ5 x1 
AGACATTACTGCCGGGAGTGTTGAGTGAAGGGACCA---------GGTGAGTAATTCCCGGGAGCGAAGCTTGTTCAAGGCCCTGCTC  Δ9 x1 
AGACATTACTGCCGGGAGTGTTGAGTGAAGGGACCA---------GGTGAGTAATT-CCGGGAGCGAAGCTTGTTCAAGGCCCTGCTC  Δ10 x1 
 
SLC25A20																									Mutations	in	12	of	542	sequences	≈	2.2% 
AAGCCAGGACGGCCCGAGAACTGACAGACGGAGTGACAGACGGACTGACCATGGCCGACCAGCCAAAACCCATCAGCCCGCTCAAGAA  WT 
AAGCCAGGACGGCCCGAGAACTGACAGACGGAGTGACA--------GACCATGGCCGACCAGCCAAAACCCATCAGCCCGCTCAAGAA  Δ8 x3 
AAGCCAGGACGGCCCGAGAACTGACAGACGGAGTGACAGACG----GACCATGGCCGACCAGCCAAAA-CCATCAGCCCGCTCAAGAA  Δ5 x1 
AAGCCAGGACGGCCCGAGAACTGACAGACGGAGTGACAGACG--------------GACCAGCCAAAACCCATCAGCCCGCTCAAGAA  Δ14 x1 
AAGCCAGGACGGCCCGAGAACTGACAGACGGAGTGACAGAC-GACTG-----------CCAcaCAAAACCCATCAGCCCGCTCAAGAA  Δ12 (Δ14 +2) x1 
AAGCCAGGACGGCCCGAGAACTGACAGACGGAGTGACAGtCGG-----CCATGGCCGACCAGCCAAAACCCATCAGCCCGCTCAAGAA  Δ5 (Δ6 +1) x1 
 SLC25A4																										Mutations	in	85	of	1114	sequences	≈	7.6% 
CGAACGGGCTGCCTGCGGGCTGAGAGCGTCGAGCTGTCACCATGGGTGATCACGCTTGGAGCTTCCTAAAGGACTTCCTGGCCGGGGG  WT 
CGAACGGGCTGCCTGCGGGCTGAGAGCGTCGAGC------------TGATCACGCTTGGAGCTTCCTAAAGGACTTCCTGGCCGGGGG  Δ12 x9 
CGAACGGGCTGCCTGCGGGCTGAGAGCGTCGAGCTG-------------TCACGCTTGGAGCTTCCTAAAGGACTTCCTGGCCGGGGG  Δ13 x7 
CGAACGGGCTGCCTGCGGGCTGAGAGCGTCGAGCTGTCACCAtgggTGGGTGATCACGCTTGGAGCTTCCTAAAGGACTTCCTGGCCG  +4 x4 
CGAACGGGCTGCCTGCGGGCTGAGAGCGTCGAGCTGTCACCA--------------TGGAGCTTCCTAAAGGACTTCCTGGCCGGGGG  Δ14 x3 
CGAACGGGCTGCCTGCGGGCTGAGAGCGTCGA---------------------GCTTGGAGCTTCCTAAAGGACTTCCTGGCCGGGGG  Δ21 x3 
 SURF1																												Mutations	in	12	of	310	sequences	≈	3.9% 
CCCGCGGGGCCGGGTGCGATGGCGGCGGTGGCTGCGTTGCAGCTGGGGCTGCGGGCGGCGGGGCTGGGACGGGTGAGCGCCGGGTGCG  WT 
CGGG---------------------/ /---------------------TGCG----------------------------GGGTGCG  Δ141 x2 
CCCGCGGGGCCGGGTGCGATGGCGGCGGTGGCTGCGTTGCAGCT-GGGCT----GCGGCGGGGCTGGGACGGGTGAGCGCCGGGTGCG  Δ5 x1 
CCCGCGGGGCCGGGTGCGATGGCGGCGGTGGCTGCGTTGCAGCT--------GGGCtGCGcGGCTGGGACGGGTGAGCGCCGGGTGCG  Δ8 (Δ10 +2) x1 
CCCGCGGGGCCGGGTGCGATGGCGGCGGTGGCTGCGTTGCAggtgtagtgGCTtgcaggtgcaggtgtagGtGGCTGCGGGCGGCGGG  +26 (Δ1 +27) x1 
CCCGCGGGGCCGGGTGCGATGGCGGCGGTGGCTGCG-TGCAGCTG-----GCGGGCGGC---GCTGGGACGGGTGAGCGCCGGGTGCG  Δ9 x1 
 SYNE1																												Mutations	in	15	of	3122	sequences	≈	0.5% 
TTGGTGTTGGCTTCGTGCTTCCGGAGGGACCATGGCAACCTCCAGAGGGGCCTCCCGGTGTCCTCGGGATATCGCCAATGTGATGCAG  WT 
TTGGTGTTGGCTTCGTGCTTCCGGAGGGACCATGGCAA------------CCTCCCGGTGTCCTCGGGATATCGCCAATGTGATGCAG  Δ12 x2 
TTGGTGTTGGCTTCGTGCTTCCGGAGGGACCATGGCAACCTCCAGAGG---CTCCCGGTGTCCTCGGGATATCGCCAATGTGATGCAG  Δ3 x1 
TTGGTGTTGGCTTCGTGCTTCCGGAGGGACCATGGCAACCTCCAGA---GCCTcCCCGGTGTCCTCGGGATATCGCCAATGTGATGCA  Δ2 (Δ3 +1) x1 
TTGGTGTTGGCTTCGTGCTTCCGGAGGGACCATGGCAACCTCCA------------GGTGTCCTCGGGATATCGCCAATGTGATGCAG  Δ12 x1 
TTGGTGTTGGCTTCGTGCTTCCGGAGGGACCATGGCAA-aTC--------aCTCCCGGTGTCCTCGGGATATCGCCAATGTGATGCAG  Δ9 (Δ11 +2) x1 	TAZ																														Mutations	in	38	of	4160	sequences	≈	0.9% 
CCACAGGCCGGCCCGGGGCGCTGGGAGCGCCGGCCGCGGGCCGGGTGGGGATGCCTCTGCACGTGAAGTGGCCGTTCCCCGCGGTGCC  WT 
CCACAGGCCGGCCCGGGGCGCTGGGA--------------------------GCCTCTGCACGTGAAGTGGCCGTTCCCCGCGGTGCC  Δ26 x3 
CCACAGGCCGGCCC--------------------------------GGGGATGCCTCTGCACGTGAAGTGGCCGTTCCCCGCGGTGCC  Δ32 x3 
CCACAGGCCGGCCCGGGGCGCTGGGAGCGCCGGCCGCGGGCCGGGT----ATGCCTCTGCACGTGAAGTGGCCGTTCCCCGCGGTGCC  Δ4 x2 
CCACAGGCCGGCCCGGGGCGCTGGGAGCGCCGGCCGCGGGCCGGG---------CTCTGCACGTGAAGTGGCCGTTCCCCGCGGTGCC  Δ9 x2 
CCACAGGCCGGCCCGGGGCGCTGGG-GaGCtG-----GGGC---GctGGGATGCCTCTGCACGTGAAGTGGCCGTTCCCCGCGGTGCC  Δ9 (Δ13 +4) x2 
 TBX1																													Mutations	in	254	of	4843	sequences	≈	5.2% 
ACCGGGTGAAGCTTCGCTGGCTGCCAGGATCCCCGGCAGGGATGCACTTCAGCACCGTCACCAGGGACATGGAAGGTGAGCCTCCAGG  WT 
ACCGGGTGAAGCTTCGCTGGCTGCCAGGATCCCCG----------------GCACCGTCACCAGGGACATGGAAGGTGAGCCTCCAGG  Δ16 x16 
ACCGGGTGAAGCTTCGCTGGCTGCCAGGATCC----------------------CCGTCACCAGGGACATGGAAGGTGAGCCTCCAGG  Δ22 x12 
ACCGGGTGAAGCTTCGCTGGCTGCCAGGATCCCCGG-------------CAGCACCGTCACCAGGGACATGGAAGGTGAGCCTCCAGG  Δ13 x11 
ACCGGGTGAAGCTTCGCTGGCTGCCAGGATCCCCGGCAGGGATgcaGCACTTCAGCACCGTCACCAGGGACATGGAAGGTGAGCCTCC  +3 x10 
ACCGGGTGAAGCTTCGCTGGCTGCCAGGATCCCCGG----------------------CACCAGGGACATGGAAGGTGAGCCTCCAGG  Δ22 x7 
 TBX20																												Mutations	in	553	of	3624	sequences	≈	15.3% 
AGTTCGGACGACCCCGTCCCTGGCCAGGACCGCGTGCTGGGGACCATGGAGTTCACGGCGTCCCCCAAGCCCCAACTCTCCTCCCGGG  WT 
AGTTCGGACGACCCCGTCCCTGGCCAGGACCGCGTGC---------TGGAGTTCACGGCGTCCCCCAAGCCCCAACTCTCCTCCCGGG  Δ9 x48 
AGTTCGGACGACCCCGTCCCTGGCCAGGACCGCGTGCTGGGGaccACCATGGAGTTCACGGCGTCCCCCAAGCCCCAACTCTCCTCCC  +3 x29 
AGTTCGGACGACCCCGTCCCTGGCCAGGACCGCGTGCTGG-------GGAGTTCACGGCGTCCCCCAAGCCCCAACTCTCCTCCCGGG  Δ7 x21 
AGTTCGGACGACCCCGTCCCTGGC-----------------------------/ /-----------------------------CAA  Δ244 x20 
AGTTCGGACGACCCCGTCCCTGGCCAGGACCGCGTGC---------TGGAGTTCACGGCGT-CCCCAAGCCCCAACTCTCCTCCCGGG  Δ10 x14 	TBX5																													Mutations	in	266	of	549	sequences	≈	48.5% 
CCTTGCGCGGGCACAGGGCCCTGGGCGCACCATGGCCGACGCAGACGAGGGCTTTGGCCTGGCGCACACGCCTCTGGAGCCTGACGCA  WT 
CCTTGCGCGGGCACAGG--------------------------------/ /---------------------------------GCC  Δ337 x20 
CCTTGCGCGGGCACAGGGCCCTGGGCGCA--------------------------/ /---------------------------CCA  Δ313 x17 
CCTTGCGCGGGCACAGGGCCCTGGGCGCA--------------------------/ /---------------------------CCT  Δ292 x17 
CCCA---------------------------------------/ /---------------------------------------TCT  Δ380 x14 
CCTTGCGCGGGCACAGGGCCCTGGGCGCACCATGGCCGACGCAGACG-----------------/ /------------------ATC  Δ265 x14 
 TCAP																													Mutations	in	40	of	3026	sequences	≈	1.3% 
CCTGGGAGGGGAGAGAGAATGAGGAGTGATCATGGCTACCTCAGAGCTGAGCTGCGAGGTGTCGGAGGAGAACTGTGAGCGCCGGGAG  WT 
CCTGGGAGGGGAGAGAGAATGAGGAGTGATCATGGCTAC-------CTGAGCTGCGAGGTGTCGGAGGAGAACTGTGAGCGCCGGGAG  Δ7 x11 
CCTGGGAGGGGAGAGAGAATGAGGAGTGATCATGGCTACCTCAGAGCTG----GCGAGGTGTCGGAGGAGAACTGTGAGCGCCGGGAG  Δ4 x2 
CCTGGGAGGGGAGAGAGAATGAGGAGTGATCATGGCTACCTCAG----GAGCTGCGAGGTGTCGGAGGAGAACTGTGAGCGCCGGGAG  Δ4 x1 
CCTGGGAGGGGAGAGAGAATGAGGAGTGATCATGGCTACCTCA-----GAGCTGCGAGGTGTCGGAGGAGAACTGTGAGCGCCGGGAG  Δ5 x1 
CCTGGGAGGGGAGAGAGAATGAGGAGTGATCATGGCTACCTCagaAGAGCTGAGCTGCGAGGTGTCGGAGGAGAACTGTGAGCGCCGG  +3 x1 
   
 TGFB3																												Mutations	in	446	of	3334	sequences	≈	13.4% 
TTCCTCTCCAGGCCTTGCCGTCCCCCTGGCCTCTCTTCCCAGCTCACACATGAAGATGCACTTGCAAAGGGCTCTGGTGGTCCTGGCC  WT 
TTCCTCTCCAGGCCTTGCCGTCCCCCTGGCCTCTCTTCCCAGctcaCTCACACATGAAGATGCACTTGCAAAGGGCTCTGGTGGTCCT  +4 x16 
TTCCTCTCCAGGCCTTGCCGTCCCCCTGGCCTCTCTTCC-----CACACATGAAGATGCACTTGCAAAGGGCTCTGGTGGTCCTGGCC  Δ5 x15 
TTCCTCTCCAGGCCTTGCCGTCCCCCTGGCCTCTCTTCC---------CATGAAGATGCACTTGCAAAGGGCTCTGGTGGTCCTGGCC  Δ9 x15 
TTCCTCTCCAGGCCTTGCCGTCCCCCTGGCCTCTCTTCC-------CACATGAAGATGCACTTGCAAAGGGCTCTGGTGGTCCTGGCC  Δ7 x11 
TTCCTCTCCAGGCCTTGCCGTCCCCCTGGCCTCTCTTCCCAGCtcaTCACACATGAAGATGCACTTGCAAAGGGCTCTGGTGGTCCTG  +3 x7 
 TMEM43																											Mutations	in	37	of	1524	sequences	≈	2.4% 
GGCGGCGGCAGCGAGCCGGGTCCCACCATGGCCGCGAATGTGAGTATCCCCGGGCCAGCCGGGCCACACCCAGGCTTCCCCGTCGCCC  WT 
GGCGGCGGCAGCGAGCCGGGTCCCACCATGGCCGCGAATGTGAGTATCCCC------GCCGGGCCACACCCAGGCTTCCCCGTCGCCC  Δ6 x1 
GGCGGCGGCAGCGAGCCGGGTCCCACCATGGCCGCGAATGTGAGTATC----GGCCAGCCGGGCCACACCCAGGCTTCCCCGTCGCCC  Δ4 x1 
GGCGGCGGCAGCGAGCCGGGTCCCACCATGGCCGCGAATGTGAGT-TCC----GgCAGCCGG--CACACCCAGGCTTCCCCGTCGCCC  Δ7 (Δ8 +1) x1 
GGCGGCGGCAGCGAGCCGGGTCCCACCATGGCCGCGAATGT---------------AtCCGGGCCgACACCCAGGCTTCCCCGTCGCC  Δ14 (Δ16 +2) x1 
GGCGGCGGCAGCGAGCCGGGTCCCACCATGGCCGCGAATG-----AT---------tGCCGGGCCACACCCAGGCTTCCCCGTCGCCC  Δ14 (Δ15 +1) x1 
 TMPO																													Mutations	in	118	of	2337	sequences	≈	5% 
GTGGGGAGGGGGCTTCGCAGATCCCCGAGATGCCGGAGTTCCTGGAAGACCCCTCGGTCCTGACAAAAGACAAGTTGAAGAGTGAGTT  WT 
GTGGGGAGGGGGCTTCGCAGATCCCCGAGATGCCGGAGTT----------CCCTCGGTCCTGACAAAAGACAAGTTGAAGAGTGAGTT  Δ10 x5 
GTGGGGAGGGGGCTTCGCAGATCCCCGAGATGCCGGAGTTCCT----GAaCCCTCGGTCCTGACAAAAGACAAGTTGAAGAGTGAGTT  Δ4 (Δ5 +1) x3 
GTGGGGAGGGGGCTTCGCAGAT---------------------------CCCCTCGGTCCTGACAAAAGACAAGTTGAAGAGTGAGTT  Δ27 x3 
GTGGGGAGGGGGCTTCGCAGATCCCCGAGATGCCGGAGTTCCTG-----aCCCTCGGTCCTGACAAAAGACAAGTTGAAGAGTGAGTT  Δ5 (Δ6 +1) x2 
GTGGGGAGGGGGCTTCGCAGATCCCCGAGATGCCGGAGTTC-----tGAaCCCTCGGTCCTGACAAAAGACAAGTTGAAGAGTGAGTT  Δ5 (Δ7 +2) x2 
 TNNC1																												Mutations	in	243	of	3354	sequences	≈	7.2% 
TGGCAACCCCAGCAAGCTGTCCTGTGAGCCGCCAGCATGGATGACATCTACAAGGCTGCGGTGAGGGACAGGGCTGGGTAGGGCTGGG  WT 
TGGCAACCCCAGCAAGCTGTCCTGTGAGCCGCCAGCAT---------------GGCTGCGGTGAGGGACAGGGCTGGGTAGGGCTGGG  Δ15 x15 
AGCC----------------------/ /-----------------------AGGCTGCGGTGAGGGACAGGGCTGGGTAGGGCTGGG  Δ218 x9 
TGGCAACCCCAGCAAGCTGTCCTGTGAGCCGCCAG---------------CAAGGCTGCGGTGAGGGACAGGGCTGGGTAGGGCTGGG  Δ15 x8 
TGGCAACCCCAGCAAGCTGTCCTGTGAGCCGCCAGCATGGatgacATGACATCTACAAGGCTGCGGTGAGGGACAGGGCTGGGTAGGG  +5 x5 
TGGCAACCCCAGCAAGCTGTCCTGTGAGCCGCCAGCAT----------------GCTGCGGTGAGGGACAGGGCTGGGTAGGGCTGGG  Δ16 x4 	TNNI3																												Mutations	in	47	of	2759	sequences	≈	1.7% 
TCGCCCTGCCTCCTGCCATTCCCGGCCTGAGTCTCAGCATGGCGGATGGGTGAGTGATGCCCCAAGGCAGTGGGAGTTGGGGGCGACC  WT 
TCGCCCTGCCTCCTGCCATTCCCGGCCTGAGTCTCAGC-------ATGGGTGAGTGATGCCCCAAGGCAGTGGGAGTTGGGGGCGACC  Δ7 x10 
TCGCCCTGCCTCCTGCCATTCCCGGCCTGAGTCTCAGCATGGcggaCGGATGGGTGAGTGATGCCCCAAGGCAGTGGGAGTTGGGGGC  +4 x3 
TCGCCCTGCCTCCTGCCATTCCCGGCCTGAGTCTCAGCATG------GGaTGAGTGATGCCCCAAGGCAGTGGGAGTTGGGGGCGACC  Δ6 (Δ7 +1) x3 
TCGCCCTGCCTCCTGCCATTCCCGGCCTGAGTCTCAGC-------ATGGGTGAGTGATG-CCCAAGGCAGTGGGAGTTGGGGGCGACC  Δ8 x3 
TCGCCCTGCCTCCTGCCATTCCCGGCCTGAGTCTCAGCAT--------GGTGAGTGATGCCCCAAGGCAGTGGGAGTTGGGGGCGACC  Δ8 x2 
 TNNT2																												Mutations	in	67	of	510	sequences	≈	13.1% 
CCTTTGTACCTGCACTGACTTTTTTCTCCTTTTGGAGGGAGAGCAGAGACCATGTCTGACATAGAAGAGGTGGTGGAAGAGTACGAGG  WT 
CCTTTGTACCTGCACTGACTTTTTTCTCCTTTTGGAGGGAGagcAGCAGAGACCATGTCTGACATAGAAGAGGTGGTGGAAGAGTACG  +3 x5 
CCTTTGTACCTGCACTGACTTTTTTCTCCTTTTGGAGGGAGAGCAGA----------GACATAGAAGAGGTGGTGGAAGAGTACGAGG  Δ10 x3 
CCTTTGTACCTGCACTGACTTTTTTCTCCTTTTGGAGGGAGAGCAGA--------CTGACATAGAAGAGGTGGTGGAAGAGTACGAGG  Δ8 x2 
CCTTTGTACCTGCACTGACTTTTTTCTCCTTTTGGAGGGAG----cAGACCATGTCTGACATAGAAGAGGTGGTGGAAGAGTACGAGG  Δ4 (Δ5 +1) x2 
CCTTTGTACCTGCACTGACTTTTTTCTCCTTTTGGAGG-------GAGACCATGTCTGACATAGAAGAGGTGGTGGAAGAGTACGAGG  Δ7 x2 	TPM1																													Mutations	in	188	of	2913	sequences	≈	6.5% 
TGCTGCAGCCCCAGGGCCCCTCGCCGCCGCCACCATGGACGCCATCAAGAAGAAGATGCAGATGCTGAAGCTCGACAAGGAGAACGCC  WT 
TGCTGCAGCCCCAGGGCCCCTCGCCGCCGCCACCATG--------------GAAGATGCAGATGCTGAAGCTCGACAAGGAGAACGCC  Δ14 x6 
TGCTGCAGCCCCAGGGCCCCTCGCCGCCGCCACCATG-----------------GATGCAGATGCTGAAGCTCGACAAGGAGAACGCC  Δ17 x5 
TGCTGCAGCCCCAGGGCCCCTCGCCGCCGCCAC------------CAAGAAGAAGATGCAGATGCTGAAGCTCGACAAGGAGAACGCC  Δ12 x5 
TGCTGCAGCCCCAGGGCCCCTCGCCGCCGCCACCATGGAC-----------GAAGATGCAGATGCTGAAGCTCGACAAGGAGAACGCC  Δ11 x4 
TGCTGCAGCCCCAGGGCCCCTCGCCGCCGCCACCATG-----------GAAGAAGATGCAGATGCTGAAGCTCGACAAGGAGAACGCC  Δ11 x4 
 TTN																														Mutations	in	28	of	3899	sequences	≈	0.7% 
CTAATTTATTTTCTCTTCTTTTTCAGAGTGCCTAGAAAGATGACAACTCAAGCACCGACGTTTACGCAGCCGTTACAAAGCGTTGTGG  WT 
CTAATTTATTTTCTCTTCTTTTTCAGAGTGCCTAGAAAGATG----tTCAAGCACCGACGTTTACGCAGCCGTTACAAAGCGTTGTGG  Δ4 (Δ5 +1) x3 
CTAATTTATTTTCTCTTCTTTTTCAGAGTGCCTAGAAAGATGacaACAACTCAAGCACCGACGTTTACGCAGCCGTTACAAAGCGTTG  +3 x3 
CTAATTTATTTTCTCTTCTTTTTCAGAGTGCCTAGA-------------AAGCACCGACGTTTACGCAGCCGTTACAAAGCGTTGTGG  Δ13 x2 
CTAA--------------------------------------ACAACTCAAGCACCGACGTTTACGCAGCCGTTACAAAGCGTTGTGG  Δ38 x2 
CTAATTTATTTTCTCTTCTTTTTCAGAGTGCCTAGAAAGATGACA---CcAGCACCGACGTTTACGCAGCCGTTACAAAGCGTTGTGG  Δ3 (Δ4 +1) x1 
 TTR																														Mutations	in	187	of	6549	sequences	≈	2.9% 
TCACAGAAGTCCACTCATTCTTGGCAGGATGGCTTCTCATCGTCTGCTCCTCCTCTGCCTTGCTGGACTGGTATTTGTGTCTGAGGCT  WT 
TCACAGAAGTCCACTCATTCTTGGCAGGATGGCTT-----------CTCCTCCTCTGCCTTGCTGGACTGGTATTTGTGTCTGAGGCT  Δ11 x32 
TCACAGAAGTCCACTCATTCTTGGCAGGATG--------------GCTCCTCCTCTGCCTTGCTGGACTGGTATTTGTGTCTGAGGCT  Δ14 x27 
TCACAGAAGTCCACTCATTCTTGGCAGGATGGCTTCTCAT------CTCCTCCTCTGCCTTGCTGGACTGGTATTTGTGTCTGAGGCT  Δ6 x6 
TCACAGAAGTCCACTCATTCTTGGCAGGAT----------------CTCCTCCTCTGCCTTGCTGGACTGGTATTTGTGTCTGAGGCT  Δ16 x5 
GGCA---------------/ /----------------AT---------------------------CTGGTATTTGTGTCTGAGGCT  Δ124 x3 
 TXNRD2																											Mutations	in	6	of	1044	sequences	≈	0.6% 
CCCCACGACGATGGCGGCAATGGCGGTGGCGCTGCGGGGATTAGGAGGGCGCTTCCGGTGGCGGACGCAGGCCGTGGCGGGCGGGGTG  WT 
CCCCACGACGATGGCGGCAATGGCGGTGGCGCTGC--GGAT-----aGGCGCTTCCGGTGGCGGACGCAGGCCGTGGCGGGCGGGGTG  Δ7 (Δ8 +1) x1 
CCCCACGACGATGGCGGCAATGGCGGTGGCGCTGC--GGAT-----aGaCGCTTCCGGTGGCGGACGCAGGCCGTGGCGGGCGGGGTG  Δ7 (Δ9 +2) x1 
CCCCACGACGATGGCGGCAATGGCGGTGGCGCTGC---GATTAG------aCTTCCGGTGGCGGACGCAGGCCGTGGCGGGCGGGGTG  Δ9 (Δ10 +1) x1 
CCCCACGACGATGGCGGCAATGGCGGTGGCGCTGC---GAT-----aGaCGCTTCCGGTGGCGGACGCAGGCCGTGGCGGGCGGGGTG  Δ8 (Δ10 +2) x1 
CCCCACGACGATGGCGGCAATGGCGGTGGCGCT---------------GCGCTTCCGGTGGCGGACGCAGGCCGTGGCGGGCGGGGTG  Δ15 x1 
 VCL																														Mutations	in	52	of	4159	sequences	≈	1.3% 
ACTTCTCTGTCGCCCGCGGTTCGCCGCCCCGCTCGCCGCCGCGATGCCAGTGTTTCATACGCGCACGATCGAGAGCATCCTGGAGCCG  WT 
ACTTCTCTGTCGCCCGCGGTTCGCCGCCCCGCTCGCC--------GCCAGTGTTTCATACGCGCACGATCGAGAGCATCCTGGAGCCG  Δ8 x7 
ACTTCTCTGTCGCCCGCGGTTCGCCGCCCCGCTCGCCGCC-----GCCAGTGTTTCATACGCGCACGATCGAGAGCATCCTGGAGCCG  Δ5 x4 
ACTTCTCTGTCGCCCGCGGTTCGCCGCCCCGCTCGCCGCCG------------aTCATACGCGCACGATCGAGAGCATCCTGGAGCCG  Δ12 (Δ13 +1) x3 
ACTTCTCTGTCGCCCGCGGTTCGCCGCCCCGCTC-----------GCCAGTGTTTCATACGCGCACGATCGAGAGCATCCTGGAGCCG  Δ11 x2 
ACTTCTCTGTCGCCCGCGGTTCGCCGCC---------------ATGCCAGTGTTTCATACGCGCACGATCGAGAGCATCCTGGAGCCG  Δ15 x2 
 ZASP																													Mutations	in	14	of	453	sequences	≈	3.1% 
ACCCTCTCTACCCTTTGTCTGCAGAGGCGGCCGCTGACAGCACCAGCATGTCTTACAGTGTGACCCTGACTGGGCCCGGGCCCTGGGG  WT 
ACCCTCTCTACCCTTTGTCTGCAGAGGCGGCCGCTGA------CAGCATGTCTTACAGTGTGACCCTGACTGGGCCCGGGCCCTGGGG  Δ6 x4 
ACCCTCTCTACCCTTTGTCTGCAGAGGCGGCCGCTGACAGCAC---CATGTCTTACAGTGTGACCCTGACTGGGCCCGGGCCCT-GGG  Δ4 x1 
ACCCTCTCTACCCTTTGTCTGCAGAGGCGGCCGCTGACAG--CCAGCATGT-------aGTGACCCTGACTGGGCCCGGGCCCTGGGG  Δ9 (Δ10 +1) x1 
ACCCTCTCTACCCTTTGTCTGCAGAGGCGGCCGCT-----------------------/ /------------------------GGA  Δ230 x1 













































Online Table III. Predicted off-target loci in TNNT2-KO and DCM-KO iPSC clones 
 
 
GENE  PCR PRIMERS 
AMPLICON 
(bp) 
LOC286094 FW: RV: 
GTGGCACAGCAGACTTACAGG 
GCAGCCTGATATATCCCCTTCC 331 
ZNF10 FW: RV: 
GCCTTCATCAGAGATTTGACCCC 
GAGGCAGAGAACCTCCAGATAAAG 345 
ORC4 FW: RV: 
GCCAGACAGTGAGAAAGATGCAG 
GGAAGCCTTGCTGGTAACATAGTC 528 
CDC20B FW: RV: 
CCCCATGGTTAGCTGGAAAATGGA 
GTAGGGGAACTGGTGTGCTACT 520 
VAMP2 FW: RV: 
GGATGCGCCACAGAATTGGG 
TCTCCAGGACTATTGAGCCCAG 326 
CABLES1 FW: RV: 
AGAAGGGGTGCAGGTGTACTC 
ACTGTCGCGATACGGCAGCA 328 
FAT3 FW: RV: 
CGCCTTGTGAGATTTTTTCCCTGG 
CCTTGCTCAAGGTCAGCTGTATC 332 
C12ORF51 FW: RV: 
TCCTTCCCGGCCTTGCTGTA 
TGCCCATTCAGAGCAGACGC 328 
PCDH15 FW: RV: 
CAGGCATCAAGTTGGTCGTGCA 
TCCTTCTGCCTGTCCCCTTC 341 
ATXN7L2 FW: RV: 
CATCCATGCCTCCAACCCAC 
CGTTAAATGCAAGTGCGGGGAATG 332 
PCID2 FW: RV: 
CATAATGGGGACTTCCGTGGG 
GCTTGACCTTCGAGTGTTTGCC 492 
PVRL1 FW: RV: 
GGAGAGCGAGACTCTGTCTCA 
GCTGGGGAGGCAATAGGTATG 332 
SDCCAG3 FW: RV: 
GTAAAGCTGGCTCCTGTGGC 
GACTTCCTGCCAGCATGGTG 338 
KCNN3 FW: RV: 
GGGAGAAGAAGAAGAGGAAGAGG 
CTCCTCCTCCTTTTCATCATCGTC 355 
FBL FW: RV: 
TTTCAGGTCCTGGAGCTTTTGGG 
TAGGAGATGGTGTGGTGGACCAG 328 
WFDC2 FW: RV: 
AGGTGGTAAGTGGAGGGGGA 
GGCTCAGAGAGGTAAACAACATGC 339 
RNASEH2B FW: RV: 
CTGCCTCTCTGAGTGTTAACTTCC 
CTGGTGAAACGACGTGGTAGC 351 
ZNF667 FW: RV: 
CAGTTGACCCTTGAGCCATGTTAG 
GGTCACCTTACTGACACCTAAGC 365 
PZP FW: RV: 
GGGCATGAGGCTTGTTGTTCTTTG 
GGCCAAAGCGCAGAAAGCAG 377 
CASP12 FW: RV: 
GCATGGCAGTATAGAATTCCTGGG 
GAGAAGCTGAAGGATGCAGGG 377 
BARX2 FW: RV: 
GGAGCCAGCGAGAATTAAAAGGG 
ACAGGCAGGCTTTCCAGGCA 340 
ERMN FW: RV: 
CGTGTGCCATGTTCATGCTTTCC 
CTCAGCCTGTTTCTTCCAGTGC 371 
CNTN4 FW: RV: 
CTGCTATGCCTGTAGGGGTTG 
CCAGCCATCCCATTACTGGGT 359 




                     
Online Table IV. Predicted off-target loci in TBX5-KO clones 
 
 
GENE  PCR PRIMERS AMPLICON (bp) 



























































































































Online Table V. Characterization of action-potentials recordings from isogenic WT and TBX5KO  
iPSCs-derived cardiomyocytes. Results are provided as mean ± SD. Maximal diastolic potential (MDP; mV), 
action potential amplitude (APA; mV), overshoot (mV), upstroke velocity (V/sec), and action potential duration 
(APD)50, APD70 and APD90 (the time intervals required to reach 50%, 70% and 90% of repolarization). 
 
 
 WT-CMs TBX5KO-CMs 
 Ventricular (n=18) Atrial (n=4) Ventricular (n=16) Atrial (n=3) 
 
MDP (mV) -62.5 ± 6.1 -60.3 ± 3.8 -63.1 ± 4 -60.2 ± 4.7 
APA(mV) 113 ± 7.9 103.8 ± 13.2 112.6 ± 6.8 102.2 ± 6.9 
Overshoot (mV) 50.5 ± 7.1 39.2 ± 10 49.4 ± 7.3 42 ± 3.7 
Upstroke Velocity (mV) 13.6 ± 3.8 19.3 ± 8.2 13 ± 3.5 12.2 ± 4.1 
APD50 (mV) 263.4 ± 80.7 159 ± 58.7 297.6 ± 99.9 153.8 ± 35.2 
APD70 (mV) 308.2 ± 96.5 190.6 ± 70.7 353.4 ± 111.2 223.6 ± 43.4 
APD90 (mV) 337.5 ± 103.6 226.2 ± 88.5 384.4 ± 114.9 270 ± 49.8 
Cycles per minute 53.9 ± 18.5 55.8 ±33.4 51 ± 20.3 51.6 ± 8.3 
